Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• "Ten Commandments" of 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.1 passage
• 'Obliterated right ventricle': a rare case of cardiogenic shock caused by a massive right ventricular metastasis and pulmonary embolism from laryngeal squamous cell carcinoma.1 passage
• 'Small bifurcation?' CT myocardial mass volume measurements change therapeutic strategy in coronary artery disease.1 passage
• 'Ten Commandments' of ESC Syncope Guidelines 2018: The new European Society of Cardiology (ESC) Clinical Practice Guidelines for the diagnosis and management of syncope were launched 19 March 2018 at EHRA 2018 in Barcelona.1 passage
• 1000 mm2 plus aortic annulus: successful treatment of a giant bicuspid aortic valve with a Sapien 3 transcatheter heart valve.1 passage
• 16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction.1 passage
• 18F-fluorodeoxyglucose positron emission/computed tomography and computed tomography angiography in prosthetic heart valve endocarditis: from guidelines to clinical practice.1 passage
• 1970-2020: 50 years of research on the long QT syndrome-from almost zero knowledge to precision medicine.1 passage
• 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).1 passage
• 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).1 passage
• 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).1 passage
• 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).1 passage
• 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).1 passage
• 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs.1 passage
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.1 passage
• 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).1 passage
• 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).1 passage
• 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations.1 passage
• 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).1 passage
• 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the Europ1 passage
• 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).1 passage
• 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.1 passage
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).1 passage
• 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).1 passage
• 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease.1 passage
• 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.1 passage
• 3D hybrid printed models in complex congenital heart disease: 3D echocardiography and cardiovascular magnetic resonance imaging fusion.1 passage
• A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation.1 passage
• A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.1 passage
• A call to action for new global approaches to cardiovascular disease drug solutions.1 passage
• A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis.1 passage
• A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment.1 passage
• A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy.1 passage
• A common missense variant of LILRB5 is associated with statin intolerance and myalgia.1 passage
• A common variant in CCDC93 protects against myocardial infarction and cardiovascular mortality by regulating endosomal trafficking of low-density lipoprotein receptor.1 passage
• A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.1 passage
• A comprehensive evaluation of the genetic architecture of sudden cardiac arrest.1 passage
• A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension.1 passage
• A decade of catheter ablation of cardiac arrhythmias in Sweden: ablation practices and outcomes.1 passage
• A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation.1 passage
• A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.1 passage
• A huge atrial thrombus in a patient with bioprosthetic valve and atrial fibrillation: something went wrong with anticoagulation therapy.1 passage
• A leucopoietic-arterial axis underlying the link between ambient air pollution and cardiovascular disease in humans.1 passage
• A man with end-stage renal failure and uncontrolled hyperparathyroidism with repeat transcatheter aortic valve replacement in a surgical bioprosthetic aortic valve while avoiding patient-prosthesis mismatch.1 passage
• A meta-analysis of continuous positive airway pressure therapy in prevention of cardiovascular events in patients with obstructive sleep apnoea.1 passage
• A minimal or maximal ablation strategy to achieve pulmonary vein isolation for paroxysmal atrial fibrillation: a prospective multi-centre randomized controlled trial (the Minimax study).1 passage
• A neurobiological mechanism linking transportation noise to cardiovascular disease in humans.1 passage
• A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy.1 passage
• A new staging system for cardiac transthyretin amyloidosis.1 passage
• A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction.1 passage
• A novel genotype-based clinicopathology classification of arrhythmogenic cardiomyopathy provides novel insights into disease progression.1 passage
• A novel machine learning-derived radiotranscriptomic signature of perivascular fat improves cardiac risk prediction using coronary CT angiography.1 passage
• A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model.1 passage
• A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.1 passage
• A novel role for myeloid endothelin-B receptors in hypertension.1 passage
• A novel transcatheter technique to treat of post-coarctation aneurysm with device occlusion of the aortic arch and descending aorta in a patient with an extra-anatomic bypass.1 passage
• A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST).1 passage
• A population-based study of cardiovascular disease mortality risk in US cancer patients.1 passage
• A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs.1 passage
• A practical risk score for early prediction of neurological outcome after out-of-hospital cardiac arrest: MIRACLE2.1 passage
• A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden fruit'.1 passage
• A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial).1 passage
• A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.1 passage
• A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.1 passage
• A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.1 passage
• A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS.1 passage
• A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.1 passage
• A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial.1 passage
• A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial†.1 passage
• A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial.1 passage
• A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions.1 passage
• A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.1 passage
• A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.1 passage
• A rare case of percutaneous exclusion of a huge aortic pseudo-aneurysm following aortic bio prosthetic endocarditis: key role of 3D echo-fluoro fusion imaging.1 passage
• A rare missense mutation in MYH6 associates with non-syndromic coarctation of the aorta.1 passage
• A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair.1 passage
• A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome.1 passage
• A score model to predict risk of events in patients with Brugada Syndrome.1 passage
• A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.1 passage
• A systematic analysis of mutual effects of transportation noise and air pollution exposure on myocardial infarction mortality: a nationwide cohort study in Switzerland.1 passage
• A systematic review and meta-analysis of the prevalence of left ventricular non-compaction in adults.1 passage
• A treatment strategy for acute myocardial infarction and personal protection for medical staff during the COVID-19 epidemic: the Chinese experience.1 passage
• ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study.1 passage
• ALPK3-deficient cardiomyocytes generated from patient-derived induced pluripotent stem cells and mutant human embryonic stem cells display abnormal calcium handling and establish that ALPK3 deficiency underlies familial cardiomyopathy.1 passage
• ALternate Site Cardiac ResYNChronization (ALSYNC): a prospective and multicentre study of left ventricular endocardial pacing for cardiac resynchronization therapy.1 passage
• AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial.1 passage
• Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction.1 passage
• Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.1 passage
• Accelerometer-derived physical activity and risk of atrial fibrillation.1 passage
• Accordion phenomenon in the descending aorta during transcatheter aortic valve replacement followed by mesenteric ischaemia.1 passage
• Accuracy of 0/1-hour algorithm for diagnosis of MI in the elderly: mono-dimensional optimization of troponin cut-offs for individual confounders or precision medicine?1 passage
• Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors.1 passage
• Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.1 passage
• Acromegaly and cardiovascular outcomes: a cohort study.1 passage
• Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis.1 passage
• Acute and midterm outcomes of the post-approval MELODY Registry: a multicentre registry of transcatheter pulmonary valve implantation.1 passage
• Acute aortic syndromes: diagnosis and management, an update.1 passage
• Acute coronary syndrome in women: rising hospitalizations in middle-aged French women, 2004-14.1 passage
• Acute myocardial infarction activates distinct inflammation and proliferation pathways in circulating monocytes, prior to recruitment, and identified through conserved transcriptional responses in mice and humans.1 passage
• Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA.1 passage
• Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management.1 passage
• Adenosine triphosphate-guided pulmonary vein isolation for atrial fibrillation: the UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate (UNDER-ATP) trial.1 passage
• Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up.1 passage
• Adipocyte fatty acid-binding protein exacerbates cerebral ischaemia injury by disrupting the blood-brain barrier.1 passage
• Adjudicating paravalvular leaks of transcatheter aortic valves: a critical appraisal.1 passage
• Adjunctive antithrombotic therapy with primary percutaneous coronary intervention in ST elevation myocardial infarction: ATOLL in perspective.1 passage
• Adjustment of the GRACE score by 2-hour post-load glucose improves prediction of long-term major adverse cardiac events in acute coronary syndrome in patients without known diabetes.1 passage
• Adult congenital heart disease: the challenges of a lifetime.1 passage
• Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.1 passage
• Aetiology and outcomes of severe right ventricular dysfunction.1 passage
• After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.1 passage
• Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.1 passage
• Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.1 passage
• Agents with vasodilator properties in acute heart failure.1 passage
• Ajmaline infusion during automated screening in Brugada syndrome and spontaneous Type 1 electrocardiogram unmasks non-suitability for subcutaneous implantable cardioverter-defibrillator.1 passage
• Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study.1 passage
• Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes.1 passage
• Alcohol consumption, sinus tachycardia, and cardiac arrhythmias at the Munich Octoberfest: results from the Munich Beer Related Electrocardiogram Workup Study (MunichBREW).1 passage
• Alert system-supported lay defibrillation and basic life-support for cardiac arrest at home.1 passage
• Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT).1 passage
• Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.1 passage
• All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study.1 passage
• Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy.1 passage
• Alterations in sympathetic nerve traffic in genetic haemochromatosis before and after iron depletion therapy: a microneurographic study.1 passage
• Altered limbic and autonomic processing supports brain-heart axis in Takotsubo syndrome.1 passage
• Altered metabolism distinguishes high-risk from stable carotid atherosclerotic plaques.1 passage
• Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial.1 passage
• Amphilimus- versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease (SUGAR trial).1 passage
• An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.1 passage
• An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis.1 passage
• An autoantibody profile detects Brugada syndrome and identifies abnormally expressed myocardial proteins.1 passage
• An automated computational image analysis pipeline for histological grading of cardiac allograft rejection.1 passage
• An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK).1 passage
• An uncommon case of acute non-traumatic paraplegia: endovascular management of an occluding thrombus in the thoracic aorta 32 years after open surgery for aortic coarctation.1 passage
• An unusual coronary embolus in a patient with prosthetic endocarditis.1 passage
• An update on interventional cardiology: management of CTO, performance of absorbable scaffolds, coronary vasomotion after DES, and antithrombotics.1 passage
• Aneurysm growth, survival, and quality of life in untreated thoracic aortic aneurysms: the effective treatments for thoracic aortic aneurysms study.1 passage
• Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study.1 passage
• Angiogenic gene therapy in cardiovascular diseases: dream or vision?1 passage
• Angiographic late lumen loss revisited: impact on long-term target lesion revascularization.1 passage
• Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.1 passage
• Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections.1 passage
• Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment.1 passage
• Anti-interleukin-1 agents for pericarditis: a primer for cardiologists.1 passage
• Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study.1 passage
• Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis.1 passage
• Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction.1 passage
• Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis.1 passage
• Anticoagulation in coronary intervention.1 passage
• Antiplatelet and direct oral anticoagulation management after coronary artery bypass graft surgery: the Cinderella of current cardiovascular trials, please show me (some) evidence.1 passage
• Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry.1 passage
• Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study.1 passage
• Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy.1 passage
• Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot.1 passage
• Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy.1 passage
• Antithrombotic therapy in diabetes: which, when, and for how long?1 passage
• Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.1 passage
• Antithrombotic treatment is associated with intraplaque haemorrhage in the atherosclerotic carotid artery: a cross-sectional analysis of The Rotterdam Study.1 passage
• Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?1 passage
• Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50-69 years.1 passage
• Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction.1 passage
• Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial.1 passage
• Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.1 passage
• Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.1 passage
• Apple Watch detecting high-grade block after transcatheter aortic valve implantation.1 passage
• Application of artificial intelligence to the electrocardiogram.1 passage
• Application of net reclassification index to non-nested and point-based risk prediction models: a review.1 passage
• Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.1 passage
• Applying evidence-based antiplatelet therapy in patients following a myocardial infarction without percutaneous coronary revascularization.1 passage
• Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial.1 passage
• Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy.1 passage
• Appropriate cohort selection and its impact on a meta-analysis evaluating the efficacy of direct oral anticoagulants post-percutaneous coronary intervention.1 passage
• Appropriateness of percutaneous revascularization of coronary chronic total occlusions: an overview.1 passage
• Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in chronic heart failure? The culmination of a 20-year journey.1 passage
• Are patients with cardiac implants protected against electromagnetic interference in daily life and occupational environment?1 passage
• Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care.1 passage
• Are the proprotein convertase subtilisin/kexin type 9 inhibitors new therapeutic chance for patients with familial hypercholesterolaemia and liver failure?1 passage
• Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study.1 passage
• Arrhythmogenic right ventricular cardiomyopathy and sports activity: from molecular pathways in diseased hearts to new insights into the athletic heart mimicry.1 passage
• Arterial stiffening is a heritable trait associated with arterial dilation but not wall thickening: a longitudinal study in the twins UK cohort.1 passage
• Artificial intelligence in the diagnosis and management of arrhythmias.1 passage
• Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.1 passage
• Asian dust exposure triggers acute myocardial infarction.1 passage
• Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention.1 passage
• Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention.1 passage
• Assessing left ventricular systolic function: from ejection fraction to strain analysis.1 passage
• Assessment and pathophysiology of microvascular disease: recent progress and clinical implications.1 passage
• Assessment of a standardized algorithm for cardiac pacing in older patients affected by severe unpredictable reflex syncopes.1 passage
• Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies.1 passage
• Association between mitochondrial DNA copy number and sudden cardiac death: findings from the Atherosclerosis Risk in Communities study (ARIC).1 passage
• Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey.1 passage
• Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort.1 passage
• Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study.1 passage
• Association between pregnancy losses in women and risk of atherosclerotic disease in their relatives: a nationwide cohort study†.1 passage
• Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.1 passage
• Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index.1 passage
• Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.1 passage
• Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study.1 passage
• Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension.1 passage
• Association between time of hospitalization with acute myocardial infarction and in-hospital mortality.1 passage
• Association is not causation: treatment effects cannot be estimated from observational data in heart failure.1 passage
• Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial.1 passage
• Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy.1 passage
• Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries.1 passage
• Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts.1 passage
• Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.1 passage
• Association of hypertension cut-off values with 10-year cardiovascular mortality and clinical consequences: a real-world perspective from the prospective MONICA/KORA study.1 passage
• Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation.1 passage
• Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial.1 passage
• Association of the combined effects of air pollution and changes in physical activity with cardiovascular disease in young adults.1 passage
• Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality: a UK Biobank observational study.1 passage
• Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis.1 passage
• Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study.1 passage
• Associations between single and multiple cardiometabolic diseases and cognitive abilities in 474 129 UK Biobank participants.1 passage
• Associations between vascular risk factors and brain MRI indices in UK Biobank.1 passage
• Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study.1 passage
• Associations of serum potassium levels with mortality in chronic heart failure patients.1 passage
• Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction.1 passage
• Atherosclerotic plaque vulnerability in the statin era.1 passage
• Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis.1 passage
• Atlas of the clinical genetics of human dilated cardiomyopathy.1 passage
• Atrial fibrillation ablation in heart failure.1 passage
• Atrial fibrillation ablation in practice: assessing CABANA generalizability.1 passage
• Atrial fibrillation and cardiac fibrosis.1 passage
• Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study.1 passage
• Atrial fibrillation as a risk factor for cognitive decline and dementia.1 passage
• Atrial fibrillation driven by micro-anatomic intramural re-entry revealed by simultaneous sub-epicardial and sub-endocardial optical mapping in explanted human hearts.1 passage
• Atrial fibrillation in heart failure: what should we do?1 passage
• Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome.1 passage
• Atrial fibrillation is associated with the fibrotic remodelling of adipose tissue in the subepicardium of human and sheep atria.1 passage
• Atrial flutter: more than just one of a kind.1 passage
• Atrial septal defect in adulthood: a new paradigm for congenital heart disease.1 passage
• Atypical position of subcutaneus implantable cardioverter-defibrillator as a solution in hypertrophic cardiomyopathy patient with initially negative electrocardiographic screening.1 passage
• Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials.1 passage
• Automated external defibrillators delivered by drones to patients with suspected out-of-hospital cardiac arrest.1 passage
• Avoiding non-responders to cardiac resynchronization therapy: a practical guide.1 passage
• BDNFVal66met polymorphism: a potential bridge between depression and thrombosis.1 passage
• Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study.1 passage
• Balloon pulmonary angioplasty with distal embolic protection device for chronic thromboembolic pulmonary hypertension.1 passage
• Balloon-expandable valve-in-valve for a deformed surgical bioprosthesis.1 passage
• Because of its association with major bleeding the ADP-binding enzyme creatine kinase should be estimated in studies of patients treated for non-ST-segment elevation acute coronary syndromes (NSTE-ACS).1 passage
• Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial.1 passage
• Beneficial effects of long-acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation: The NOVEL study.1 passage
• Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.1 passage
• Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.1 passage
• Bernard J. Gersh, Mayo Clinic, Rochester, MN, USA, provides a transatlantic perspective on the 2014 European Society of Cardiology Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy.1 passage
• Beta blockers, calcium channel blockers, and long-acting nitrates for patients with stable angina and low blood pressure levels: should this recommendation be reconsidered?1 passage
• Beta-blocker subtype and risks of perioperative adverse events following non-cardiac surgery: a nationwide cohort study.1 passage
• Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.1 passage
• Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure.1 passage
• Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).1 passage
• Big Data for cardiology: novel discovery?1 passage
• Big data from electronic health records for early and late translational cardiovascular research: challenges and potential.1 passage
• Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study.1 passage
• Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure.1 passage
• Biomechanical stress in coronary atherosclerosis: emerging insights from computational modelling.1 passage
• Bivalirudin, glycoprotein inhibitor, and heparin use and association with outcomes of primary percutaneous coronary intervention in the United Kingdom.1 passage
• Biventricular pacing after AV-node ablation for atrial fibrillation with heart failure: something old and something new, future standard, or just for the few?1 passage
• Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.1 passage
• Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.1 passage
• Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke.1 passage
• Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.1 passage
• Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial.1 passage
• Body composition and atrial fibrillation: a Mendelian randomization study.1 passage
• Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study.1 passage
• Body weight in adolescence and long-term risk of early heart failure in adulthood among men in Sweden.1 passage
• Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial).1 passage
• Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study.1 passage
• Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study.1 passage
• Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?1 passage
• Brugada syndrome genetics is associated with phenotype severity.1 passage
• Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study.1 passage
• Bystander cardiopulmonary resuscitation and long-term outcomes in out-of-hospital cardiac arrest according to location of arrest.1 passage
• C-reactive protein and clinical outcomes in patients with COVID-19.1 passage
• C1q/TNF-related protein-1: an adipokine marking and promoting atherosclerosis.1 passage
• CANTOS: One year on: When the findings of the CANTOS trial were unveiled at ESC Congress 2017 in Barcelona, there was a sense of hope that a new era in preventive cardiology was set to begin. One year on, CANTOS Principle Investigator and study author Paul M. Ridker discusses whether that optimism is being realized.1 passage
• CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice.1 passage
• COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions.1 passage
• COVID-19 is, in the end, an endothelial disease.1 passage
• COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests.1 passage
• COVID-19: from epidemiology to treatment.1 passage
• CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy.1 passage
• CXCL1-CXCR2 axis mediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration.1 passage
• Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation.1 passage
• Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy.1 passage
• Calcific aortic valve stenosis: hard disease in the heart: A biomolecular approach towards diagnosis and treatment.1 passage
• Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: the multicentre, randomized CRESCENT trial.1 passage
• Calls for a higher level of professionalism in biomedical research.1 passage
• Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry.1 passage
• Can we remove scar and fibrosis from adult human myocardium?1 passage
• Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes.1 passage
• Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?1 passage
• Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy.1 passage
• Cardiac Centre of Excellence. The West German Heart Centre in Essen.1 passage
• Cardiac amyloidosis secondary to multiple myeloma: successful sequential cardiac and autologous stem cell transplantations with excellent outcome.1 passage
• Cardiac and systemic rejuvenation after cardiosphere-derived cell therapy in senescent rats.1 passage
• Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation.1 passage
• Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry.1 passage
• Cardiac computed tomography in patients with acute chest pain.1 passage
• Cardiac diagnostic work-up of ischaemic stroke.1 passage
• Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus.1 passage
• Cardiac fibroblast activation detected by positron emission tomography/computed tomography as a possible sign of cardiotoxicity.1 passage
• Cardiac manifestations of sarcoidosis: diagnosis and management.1 passage
• Cardiac mesenchymal stromal cells are a source of adipocytes in arrhythmogenic cardiomyopathy.1 passage
• Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis.1 passage
• Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole.1 passage
• Cardiac protective effects of remote ischaemic preconditioning in children undergoing tetralogy of fallot repair surgery: a randomized controlled trial.1 passage
• Cardiac rehabilitation and survival in a large representative community cohort of Dutch patients.1 passage
• Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications.1 passage
• Cardiac resynchronization therapy non-responder to responder conversion rate in the more response to cardiac resynchronization therapy with MultiPoint Pacing (MORE-CRT MPP) study: results from Phase I.1 passage
• Cardiac structure and function and leisure-time physical activity in the elderly: The Atherosclerosis Risk in Communities Study.1 passage
• Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices.1 passage
• Cardio-Oncology Services: rationale, organization, and implementation.1 passage
• CardioPulse: 'Ten Commandments' of 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (NSTE-ACS).1 passage
• CardioPulse: What's new in the 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.1 passage
• CardioScape mapping the cardiovascular funding landscape in Europe.1 passage
• Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial.1 passage
• Cardiomyocyte renewal in the human heart: insights from the fall-out.1 passage
• Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.1 passage
• Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial.1 passage
• Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.1 passage
• Cardiorespiratory fitness, muscular strength, and obesity in adolescence and later chronic disability due to cardiovascular disease: a cohort study of 1 million men.1 passage
• Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.1 passage
• Cardiovascular conditions predisposing to infective endocarditis: time to reconsider the current risk classification system?1 passage
• Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?1 passage
• Cardiovascular disease burden from ambient air pollution in Europe reassessed using novel hazard ratio functions.1 passage
• Cardiovascular disease in Europe--epidemiological update 2015.1 passage
• Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.1 passage
• Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting.1 passage
• Cardiovascular diseases in populations: secular trends and contemporary challenges-Geoffrey Rose lecture, European Society of Cardiology meeting 2014.1 passage
• Cardiovascular dysfunction in children conceived by assisted reproductive technologies.1 passage
• Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France.1 passage
• Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists.1 passage
• Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis.1 passage
• Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study.1 passage
• Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.1 passage
• Cardiovascular manifestations of sickle cell disease.1 passage
• Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies.1 passage
• Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.1 passage
• Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.1 passage
• Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.1 passage
• Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial.1 passage
• Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout.1 passage
• Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.1 passage
• Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis.1 passage
• Cardiovascular vulnerability of childhood cancer survivors: time to progress from risk observation to risk modification.1 passage
• Carotid artery stenting: an update.1 passage
• Carotid artery wave intensity in mid- to late-life predicts cognitive decline: the Whitehall II study.1 passage
• Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries.1 passage
• Catheter ablation in patients with persistent atrial fibrillation.1 passage
• Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial.1 passage
• Catheter-based interventions for acute ischaemic stroke.1 passage
• Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy.1 passage
• Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank.1 passage
• Cause of kidney disease and cardiovascular events in a national cohort of US patients with end-stage renal disease on dialysis: a retrospective analysis.1 passage
• Causes and mechanisms of isolated mitral regurgitation in the community: clinical context and outcome.1 passage
• Causes of late mortality with dual antiplatelet therapy after coronary stents.1 passage
• Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study.1 passage
• Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation.1 passage
• Changes in coexpression of pericytes and endogenous cardiac progenitor cells from heart development to disease state.1 passage
• Changes in exercise frequency and cardiovascular outcomes in older adults.1 passage
• Changes in thrombus composition and profilin-1 release in acute myocardial infarction.1 passage
• Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.1 passage
• Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care.1 passage
• Characteristics and clinical assessment of unexplained sudden cardiac arrest in the real-world setting: focus on idiopathic ventricular fibrillation.1 passage
• Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.1 passage
• Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy.1 passage
• Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry.1 passage
• Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study).1 passage
• Childhood infection may mediate the relationship between suboptimal intrauterine growth, preterm birth, and adult cardiovascular disease.1 passage
• Chimney technique in a TAVR-in-TAVR procedure with high risk of left main artery ostium occlusion.1 passage
• Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque.1 passage
• Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis.1 passage
• Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study.1 passage
• Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.1 passage
• Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.1 passage
• Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.1 passage
• Chronic infarct size after spontaneous coronary artery dissection: implications for pathophysiology and clinical management.1 passage
• Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective.1 passage
• Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study.1 passage
• Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial.1 passage
• Chronic venous insufficiency, cardiovascular disease, and mortality: a population study.1 passage
• Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects.1 passage
• Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study.1 passage
• Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?1 passage
• Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.1 passage
• Circulating stem cells and cardiovascular outcomes: from basic science to the clinic.1 passage
• Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry.1 passage
• Climate and environmental triggers of acute myocardial infarction.1 passage
• Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis.1 passage
• Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR).1 passage
• Clinical and conceptual approaches to interpreting the findings of systematic review and meta-analysis of mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease.1 passage
• Clinical and haemodynamic outcomes of balloon-expandable transcatheter mitral valve implantation: a 7-year experience.1 passage
• Clinical application of the 4th Universal Definition of Myocardial Infarction.1 passage
• Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging.1 passage
• Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.1 passage
• Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy.1 passage
• Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group.1 passage
• Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.1 passage
• Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair.1 passage
• Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.1 passage
• Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study.1 passage
• Clinical features and survival in Takayasu's arteritis-associated pulmonary hypertension: a nationwide study.1 passage
• Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy.1 passage
• Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis.1 passage
• Clinical impact of direct stenting and interaction with thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Thrombectomy Trialists Collaboration.1 passage
• Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.1 passage
• Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea.1 passage
• Clinical implications of three-vessel fractional flow reserve measurement in patients with coronary artery disease.1 passage
• Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.1 passage
• Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial.1 passage
• Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study.1 passage
• Clinical outcomes of patients with hypothyroidism undergoing percutaneous coronary intervention.1 passage
• Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study.1 passage
• Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.1 passage
• Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction.1 passage
• Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom.1 passage
• Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study.1 passage
• Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries.1 passage
• Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry.1 passage
• Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions: A joint statement by the European Society of Cardiology, the Council on Hypertension of the European Society of Cardiology, the European Society of Hypertension, the International Society of Mountain Medicine, the Italian Society of Hypertension and the Italian Society of Mountain Medicine.1 passage
• Clinical review on triglycerides.1 passage
• Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium.1 passage
• Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium.1 passage
• Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions.1 passage
• Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions.1 passage
• Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II.1 passage
• Clinician Well-Being-addressing global needs for improvements in the health care field: a joint opinion from the American College of Cardiology, American Heart Association, European Society of Cardiology, World Heart Federation.1 passage
• Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.1 passage
• Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation.1 passage
• Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes.1 passage
• Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy.1 passage
• Coexistence and outcome of coronary artery disease in Takotsubo syndrome.1 passage
• Colchicine and the heart.1 passage
• Comment to: Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.1 passage
• Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.1 passage
• Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease.1 passage
• Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis.1 passage
• Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.1 passage
• Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration.1 passage
• Comparison of coronary artery calcification, carotid intima-media thickness and ankle-brachial index for predicting 10-year incident cardiovascular events in the general population.1 passage
• Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of MIcrovascular Dysfunction in Aortic Stenosis (PRIMID AS) Study.1 passage
• Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes.1 passage
• Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.1 passage
• Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial.1 passage
• Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study.1 passage
• Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation.1 passage
• Comparison of vascular closure devices for access site closure after transfemoral aortic valve implantation.1 passage
• Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure.1 passage
• Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials.1 passage
• Composition of nocturnal hypoxaemic burden and its prognostic value for cardiovascular mortality in older community-dwelling men.1 passage
• Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications.1 passage
• Computed tomography for planning transcatheter tricuspid valve therapy.1 passage
• Concomitant mitral annular calcification and severe aortic stenosis: prevalence, characteristics and outcome following transcatheter aortic valve replacement.1 passage
• Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).1 passage
• Conduction disturbances following trancatheter aortic valve implantation: increasing the 'pace' towards prospective evidence.1 passage
• Congestive pulmonary oedema during venoarterial extracorporeal membrane oxygenation support: a plea for balloon atrial septostomy.1 passage
• Consequences of implementing a cardiac troponin assay with improved sensitivity at Swedish coronary care units: an analysis from the SWEDEHEART registry.1 passage
• Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction.1 passage
• Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS guidelines on myocardial revascularization.1 passage
• Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry.1 passage
• Contemporary trends in the management of aortic stenosis in the USA.1 passage
• Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).1 passage
• Continuous thermodilution to assess absolute flow and microvascular resistance: validation in humans using [15O]H2O positron emission tomography.1 passage
• Contraception and cardiovascular disease.1 passage
• Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial.1 passage
• Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes.1 passage
• Contribution of income and job strain to the association between education and cardiovascular disease in 1.6 million Danish employees.1 passage
• Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study.1 passage
• Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.1 passage
• Conversion to and maintenance of sinus rhythm do not yield a significant increase in stroke-volume in HFREF patients, whose heart works on the flat branch of Frank-Starling curve, thereby making the retrieval of the atrial mechanical contribution in this subset a substantially futile choice.1 passage
• Coping strategies and risk of cardiovascular disease incidence and mortality: the Japan Public Health Center-based prospective Study.1 passage
• Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?1 passage
• Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study.1 passage
• Coronary autoregulation and assessment of stenosis severity without pharmacological vasodilation.1 passage
• Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study.1 passage
• Coronary compression caused by extrinsic adventitial damage: case of an early complication of trans-catheter tricuspid annuloplasty with cardioband device.1 passage
• Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease.1 passage
• Coronary evaginations and peri-scaffold aneurysms following implantation of bioresorbable scaffolds: incidence, outcome, and optical coherence tomography analysis of possible mechanisms.1 passage
• Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis.1 passage
• Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study.1 passage
• Coronary high-intensity plaque on T1-weighted magnetic resonance imaging and its association with myocardial injury after percutaneous coronary intervention.1 passage
• Coronary microcirculatory pathophysiology: can we afford it to remain a black box?1 passage
• Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.1 passage
• Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg?1 passage
• Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases.1 passage
• Coronary microvascular obstruction in acute myocardial infarction.1 passage
• Coronary plaque quantification and fractional flow reserve by coronary computed tomography angiography identify ischaemia-causing lesions.1 passage
• Coronary pressure and flow relationships in humans: phasic analysis of normal and pathological vessels and the implications for stenosis assessment: a report from the Iberian-Dutch-English (IDEAL) collaborators.1 passage
• Coronavirus disease 2019 in adults with congenital heart disease: a position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease.1 passage
• Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme.1 passage
• Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.1 passage
• Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).1 passage
• Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.1 passage
• Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.1 passage
• Cracking (the code of) coronary artery calcification to win the last battle of percutaneous coronary intervention: still in the middle of a rocky road.1 passage
• Critical isthmus of ventricular tachycardia covered by transcatheter pulmonary valve in a patient with tetralogy of Fallot.1 passage
• Crucial role for Nox2 and sleep deprivation in aircraft noise-induced vascular and cerebral oxidative stress, inflammation, and gene regulation.1 passage
• Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial.1 passage
• Culotte stenting vs. TAP stenting for treatment of de-novo coronary bifurcation lesions with the need for side-branch stenting: the Bifurcations Bad Krozingen (BBK) II angiographic trial.1 passage
• Culprit lesion thrombus burden after manual thrombectomy or percutaneous coronary intervention-alone in ST-segment elevation myocardial infarction: the optical coherence tomography sub-study of the TOTAL (ThrOmbecTomy versus PCI ALone) trial.1 passage
• Culprit mistaken: development of a traumatic coronary aneurysm after mismatched culprit lesion-PCI for plaque rupture.1 passage
• Current but not past smoking increases the risk of cardiac events: insights from coronary computed tomographic angiography.1 passage
• Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects.1 passage
• Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients.1 passage
• Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS).1 passage
• Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.1 passage
• Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes.1 passage
• DUSP26 induces aortic valve calcification by antagonizing MDM2-mediated ubiquitination of DPP4 in human valvular interstitial cells.1 passage
• Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.1 passage
• Daily remote monitoring of implantable cardioverter-defibrillators: insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST).1 passage
• Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation.1 passage
• Day-to-day measurement of physical activity and risk of atrial fibrillation.1 passage
• Death of a child and the risk of atrial fibrillation: a nationwide cohort study in Sweden.1 passage
• Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy.1 passage
• Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome.1 passage
• Deep learning for cardiovascular medicine: a practical primer.1 passage
• Defective cholesterol metabolism in haematopoietic stem cells promotes monocyte-driven atherosclerosis in rheumatoid arthritis.1 passage
• Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial.1 passage
• Deferred vs. performed revascularization for coronary stenosis with grey-zone fractional flow reserve values: data from the IRIS-FFR registry.1 passage
• Deficiency of the T cell regulator Casitas B-cell lymphoma-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death.1 passage
• Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.1 passage
• Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes.1 passage
• Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications.1 passage
• Deleterious effects of viral pneumonia on cardiovascular system.1 passage
• Deletion of delta-like 1 homologue accelerates fibroblast-myofibroblast differentiation and induces myocardial fibrosis.1 passage
• Demonstration of the disease activity by serial carotid artery ultrasonography, magnetic resonance imaging and 18-fluoro-deoxyglucose positron emission tomography in a Behçet's disease patient with carotid artery stenosis.1 passage
• Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).1 passage
• Depression requiring anti-depressant drug therapy in adult congenital heart disease: prevalence, risk factors, and prognostic value.1 passage
• Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis.1 passage
• Detecting right ventricular dysfunction in patients diagnosed with low-risk pulmonary embolism: is routine computed tomographic pulmonary angiography sufficient?1 passage
• Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients.1 passage
• Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.1 passage
• Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.1 passage
• Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.1 passage
• Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis.1 passage
• Determinants of outcomes following surgery for type A acute aortic dissection: the UK National Adult Cardiac Surgical Audit.1 passage
• Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.1 passage
• Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study.1 passage
• Development and validation of two SCORE-based cardiovascular risk prediction models for Eastern Europe: a multicohort study.1 passage
• Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group.1 passage
• Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history.1 passage
• Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke.1 passage
• Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function.1 passage
• Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease.1 passage
• Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.1 passage
• Diagnosis of malignant coronary vasospasm by 12-lead Holter electrocardiogram and optical coherence tomography.1 passage
• Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy.1 passage
• Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis.1 passage
• Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis.1 passage
• Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.1 passage
• Diastolic pressure ratio: new approach and validation vs. the instantaneous wave-free ratio.1 passage
• Dietary counselling has no effect on cardiovascular risk factors among Chinese Grade 1 hypertensive patients: a randomized controlled trial.1 passage
• Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease.1 passage
• Differences in initiation and discontinuation of preventive medications and use of non-pharmacological interventions after acute coronary syndrome among migrants and Danish-born.1 passage
• Different perspectives on outcomes in patients with non-ST-elevation myocardial infarction when observed in clinical trials and in real life.1 passage
• Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.1 passage
• Differential clinical features and long-term prognosis of acute aortic syndrome according to disease entity.1 passage
• Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.1 passage
• Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study.1 passage
• Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translational OPTICO-ACS study.1 passage
• Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis.1 passage
• Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis.1 passage
• Digoxin-associated mortality: a systematic review and meta-analysis of the literature.1 passage
• Digoxin-mortality: randomized vs. observational comparison in the DIG trial.1 passage
• Direct visualization of the laceration of a dissected pulmonary artery by transthoracic echocardiography: comparison with surgical findings.1 passage
• Discrimination of patients with type 2 myocardial infarction.1 passage
• Discriminatory cardiac arrest care? Patients with low socioeconomic status receive delayed cardiopulmonary resuscitation and are less likely to survive an in-hospital cardiac arrest.1 passage
• Disordered haematopoiesis and athero-thrombosis.1 passage
• Distance to invasive heart centre, performance of acute coronary angiography, and angioplasty and associated outcome in out-of-hospital cardiac arrest: a nationwide study.1 passage
• Distinct child-to-adult body mass index trajectories are associated with different levels of adult cardiometabolic risk.1 passage
• Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors?1 passage
• Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?1 passage
• Does gut microbiota affect atrial rhythm? Causalities and speculations.1 passage
• Does increased 24-h ambulatory heart rate identify de facto neurogenic hypertension, and facilitate selection of hypertensive patients for renal denervation?1 passage
• Does night-time aircraft noise trigger mortality? A case-crossover study on 24 886 cardiovascular deaths.1 passage
• Does pregnancy complication history improve cardiovascular disease risk prediction? Findings from the HUNT study in Norway.1 passage
• Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?1 passage
• Driving following defibrillator implantation: a nationwide register-linked survey study.1 passage
• Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score.1 passage
• Duration and life-stage of antibiotic use and risk of cardiovascular events in women.1 passage
• Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.1 passage
• EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic.1 passage
• EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.1 passage
• EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial.1 passage
• ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Perioperative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery.1 passage
• ESC Working Group Position Paper: Transcatheter adult congenital heart disease interventions: organization of care – recommendations from a Joint Working Group of the European Society of Cardiology (ESC), European Association of Pediatric and Congenital Cardiology (AEPC), and the European Association of Percutaneous Cardiac Intervention (EAPCI).1 passage
• ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.1 passage
• EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT).1 passage
• Early ST elevation myocardial infarction in non-capable percutaneous coronary intervention centres: in situ fibrinolysis vs. percutaneous coronary intervention transfer.1 passage
• Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension.1 passage
• Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis.1 passage
• Early diagnosis of acute coronary syndrome.1 passage
• Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.1 passage
• Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study.1 passage
• Early goal-directed haemodynamic optimization of cerebral oxygenation in comatose survivors after cardiac arrest: the Neuroprotect post-cardiac arrest trial.1 passage
• Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves.1 passage
• Early invasive coronary angiography and acute ischaemic heart failure outcomes.1 passage
• Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study.1 passage
• Early vascular damage from smoking and alcohol in teenage years: the ALSPAC study.1 passage
• Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.1 passage
• Editor's Note: Relates to: 'Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease : Consensus Statement of the European Atherosclerosis Society '.1 passage
• Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.1 passage
• Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.1 passage
• Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.1 passage
• Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study.1 passage
• Effect of 5 years of exercise training on the cardiovascular risk profile of older adults: the Generation 100 randomized trial.1 passage
• Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.1 passage
• Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.1 passage
• Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.1 passage
• Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study.1 passage
• Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial.1 passage
• Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation.1 passage
• Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).1 passage
• Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.1 passage
• Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.1 passage
• Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.1 passage
• Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial.1 passage
• Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.1 passage
• Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study.1 passage
• Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population.1 passage
• Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.1 passage
• Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension.1 passage
• Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results.1 passage
• Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.1 passage
• Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial.1 passage
• Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.1 passage
• Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study.1 passage
• Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.1 passage
• Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.1 passage
• Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily.1 passage
• Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study).1 passage
• Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.1 passage
• Effects of canagliflozin on human myocardial redox signalling: clinical implications.1 passage
• Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.1 passage
• Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study.1 passage
• Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.1 passage
• Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.1 passage
• Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.1 passage
• Effects of gaseous and solid constituents of air pollution on endothelial function.1 passage
• Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.1 passage
• Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial.1 passage
• Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial.1 passage
• Effects of paediatric HIV infection on childhood vasculature.1 passage
• Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry.1 passage
• Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.1 passage
• Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes.1 passage
• Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.1 passage
• Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.1 passage
• Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials.1 passage
• Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.1 passage
• Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.1 passage
• Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.1 passage
• Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial.1 passage
• Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial.1 passage
• Efficacy of a web-based intervention for improving psychosocial well-being in patients with implantable cardioverter-defibrillators: the randomized controlled ICD-FORUM trial.1 passage
• Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.1 passage
• Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement.1 passage
• Electrical cardiac injuries: current concepts and management.1 passage
• Electrical risk score beyond the left ventricular ejection fraction: prediction of sudden cardiac death in the Oregon Sudden Unexpected Death Study and the Atherosclerosis Risk in Communities Study.1 passage
• Electrocardiogram screening for aortic valve stenosis using artificial intelligence.1 passage
• Electrocardiographic anterior T-wave inversion in athletes of different ethnicities: differential diagnosis between athlete's heart and cardiomyopathy.1 passage
• Electromechanical window negativity in genotyped long-QT syndrome patients: relation to arrhythmia risk.1 passage
• Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults.1 passage
• Elevated high-density lipoprotein in adolescents with Type 1 diabetes is associated with endothelial dysfunction in the presence of systemic inflammation.1 passage
• Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study.1 passage
• Emergency department management of patients with adult congenital heart disease: a consensus paper from the ESC Working Group on Adult Congenital Heart Disease, the European Society for Emergency Medicine (EUSEM), the European Association for Cardio-Thoracic Surgery (EACTS), and the Association for Acute Cardiovascular Care (ACVC).1 passage
• Emerging causes and risk factors of heart failure: amyloidosis, myocarditis, immune checkpoint inhibitors, air pollution, and visceral adipose tissue.1 passage
• Emerging roles for RNA-binding proteins as effectors and regulators of cardiovascular disease.1 passage
• Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.1 passage
• Endomyocardial fibrosis masquerading as metastatic colorectal tumour; myocardial tissue characterization pivotal in guiding urgent surgical management.1 passage
• Endothelial SIRT6 blunts stroke size and neurological deficit by preserving blood-brain barrier integrity: a translational study.1 passage
• Endothelial shear stress 5 years after implantation of a coronary bioresorbable scaffold.1 passage
• Endovascular grafts for abdominal aortic aneurysm.1 passage
• Endovascular therapy for acute ischaemic stroke: a systematic review and meta-analysis of randomized trials.1 passage
• Enhancement patterns detected by multidetector computed tomography are associated with microvascular obstruction and left ventricular remodelling in patients with acute myocardial infarction.1 passage
• Environmental stressors and cardio-metabolic disease: part I-epidemiologic evidence supporting a role for noise and air pollution and effects of mitigation strategies.1 passage
• Environmental stressors and cardio-metabolic disease: part II-mechanistic insights.1 passage
• Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions.1 passage
• Epidemiology report: trends in sex-specific cerebrovascular disease mortality in Europe based on WHO mortality data.1 passage
• Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena.1 passage
• Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies.1 passage
• Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS?1 passage
• Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.1 passage
• Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking.1 passage
• EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring.1 passage
• European Association of Preventive Cardiology (EAPC) and European Association of Cardiovascular Imaging (EACVI) joint position statement: recommendations for the indication and interpretation of cardiovascular imaging in the evaluation of the athlete's heart.1 passage
• European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology.1 passage
• European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE).1 passage
• European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with th1 passage
• European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis.1 passage
• European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.1 passage
• European Society of Cardiology: Cardiovascular Disease Statistics 2017.1 passage
• European Society of Cardiology: Cardiovascular Disease Statistics 2019.1 passage
• European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism.1 passage
• European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions.1 passage
• Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death.1 passage
• Evaluation of individual plaque risk based on plaque anatomic and biomechanical characteristics: methodologies and clinical applications are approaching an inflection point.1 passage
• Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.1 passage
• Evidence to support magnetic resonance conditional labelling of all pacemaker and defibrillator leads in patients with cardiac implantable electronic devices.1 passage
• Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey.1 passage
• Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction.1 passage
• Exercise and the heart: the good, the bad, and the ugly.1 passage
• Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial.1 passage
• Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease.1 passage
• Exercise-induced right ventricular dysfunction is associated with ventricular arrhythmias in endurance athletes.1 passage
• Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans.1 passage
• Expert recommendations on the assessment of wall shear stress in human coronary arteries: existing methodologies, technical considerations, and clinical applications.1 passage
• Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction.1 passage
• Expression of smooth muscle cell markers and co-activators in calcified aortic valves.1 passage
• External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.1 passage
• Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest in relation to organ donation.1 passage
• Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest: a registry study.1 passage
• Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest: do not neglect potential for organ donation!1 passage
• Extreme electrocardiographic changes in congenital complete absence of pericardium with complex coronary artery disease: multiparametric cardiovascular magnetic resonance imaging guiding diagnosis and treatment.1 passage
• Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies.1 passage
• Familial co-occurrence of congenital heart defects follows distinct patterns.1 passage
• Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.1 passage
• Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines?1 passage
• Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.1 passage
• Feasibility of using deep learning to detect coronary artery disease based on facial photo.1 passage
• Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.1 passage
• Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.1 passage
• Fibrosis as measured by the biomarker, tissue inhibitor metalloproteinase-1, predicts mortality in Age Gene Environment Susceptibility-Reykjavik (AGES-Reykjavik) Study.1 passage
• Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study.1 passage
• Finding concordance in discord: the value of discordant invasive and echocardiographic pulmonary artery pressure measurements with severe tricuspid regurgitation.1 passage
• First in human transcatheter COMBO mitral valve repair with direct ring annuloplasty and neochord leaflet implantation to treat degenerative mitral regurgitation: feasibility of the simultaneous toolbox concept guided by 3D echo and computed tomography fusion imaging.1 passage
• First report of simultaneous transcatheter aortic valve replacement, endovascular aortic aneurysm repair, and permanent pacemaker implantation after multi-vessel coronary stenting and left atrial appendage occlusion.1 passage
• First-in-man experience with real-time holographic mixed reality display of three-dimensional echocardiography during structural intervention: balloon mitral commissurotomy.1 passage
• First-in-man proof of feasibility: PCI, TAVR, and TEVAR of aortic arch with a hybrid approach through a trans-caval (cavo-aortic) access in the same procedure.1 passage
• First-in-man: successful interventional closure of severe paravalvular leakage after surgical rapid deployment aortic valve replacement.1 passage
• Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction.1 passage
• Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.1 passage
• Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme.1 passage
• Fixed low-dose ultrasound-assisted catheter-directed thrombolysis for intermediate and high-risk pulmonary embolism.1 passage
• Fluid status telemedicine alerts for heart failure: a randomized controlled trial.1 passage
• For neonatal ECG screening there is no reason to relinquish old Bazett's correction.1 passage
• Forced diuresis with matched hydration during transcatheter aortic valve implantation for Reducing Acute Kidney Injury: a randomized, sham-controlled study (REDUCE-AKI).1 passage
• Four-dimensional flow magnetic resonance imaging reveals the reduction in turbulent kinetic energy after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.1 passage
• Four-dimensional flow magnetic resonance imaging visualizes drastic change in vortex flow in the main pulmonary artery after percutaneous transluminal pulmonary angioplasty in a patient with chronic thromboembolic pulmonary hypertension.1 passage
• Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses.1 passage
• Fractional flow reserve and pressure-bounded coronary flow reserve to predict outcomes in coronary artery disease.1 passage
• Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial.1 passage
• Fractional flow reserve in clinical practice: from wire-based invasive measurement to image-based computation.1 passage
• Fractional flow reserve in patients with reduced ejection fraction.1 passage
• Fractional flow reserve to guide and to assess coronary artery bypass grafting.1 passage
• Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial.1 passage
• Fractional flow reserve, instantaneous wave-free ratio, and resting Pd/Pa compared with [15O]H2O positron emission tomography myocardial perfusion imaging: a PACIFIC trial sub-study.1 passage
• Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments.1 passage
• Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.1 passage
• Fracture risk associated with different oral anticoagulants in patients with atrial fibrillation: updated evidence from real-world observational studies and clinical trials.1 passage
• Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.1 passage
• Frailty and cardiovascular outcomes in the National Health and Aging Trends Study.1 passage
• Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort.1 passage
• Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study.1 passage
• From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2.1 passage
• From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases.1 passage
• Frontiers in lipid research: lipoprotein(a), apolipoprotein C-III and E, and PCSK9 and inflammation.1 passage
• Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease.1 passage
• Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial determinant of survival.1 passage
• Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome.1 passage
• Fundamentals in clinical coronary physiology: why coronary flow is more important than coronary pressure.1 passage
• Future cardiovascular risk prediction in women with pregnancy complications: the HUNT is on.1 passage
• Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation.1 passage
• Gender in cardiovascular medicine: chest pain and coronary artery disease.1 passage
• Gene therapy for the treatment of heart failure: promise postponed.1 passage
• Genetic defects in a His-Purkinje system transcription factor, IRX3, cause lethal cardiac arrhythmias.1 passage
• Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction.1 passage
• Genetic insight into sick sinus syndrome.1 passage
• Genetic predisposition to smoking in relation to 14 cardiovascular diseases.1 passage
• Genetic variability in the absorption of dietary sterols affects the risk of coronary artery disease.1 passage
• Genetic variants in CYP7A1 and risk of myocardial infarction and symptomatic gallstone disease.1 passage
• Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.1 passage
• Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease.1 passage
• Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality.1 passage
• Genetically modulated educational attainment and coronary disease risk.1 passage
• Genetics and genotype-phenotype correlations in Finnish patients with dilated cardiomyopathy.1 passage
• Genome-wide analysis identifies novel susceptibility loci for myocardial infarction.1 passage
• Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.1 passage
• Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs.1 passage
• Genomic correction of familial cardiomyopathy in human engineered cardiac tissues.1 passage
• Genomic prediction of coronary heart disease.1 passage
• Genotype impacts survival in Marfan syndrome.1 passage
• Geographic variations in the PARADIGM-HF heart failure trial.1 passage
• Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD(P)H oxidase.1 passage
• Global DNA methylation analysis of human atherosclerotic plaques reveals extensive genomic hypomethylation and reactivation at imprinted locus 14q32 involving induction of a miRNA cluster.1 passage
• Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction.1 passage
• Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans.1 passage
• Glycosylated apolipoprotein J in cardiac ischaemia: molecular processing and circulating levels in patients with acute ischaemic events.1 passage
• Greater decreases in cholesterol levels among individuals with high cardiovascular risk than among the general population: the northern Sweden MONICA study 1994 to 2014.1 passage
• Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.1 passage
• Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction.1 passage
• Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis.1 passage
• Gut microbial diversity is associated with lower arterial stiffness in women.1 passage
• Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors.1 passage
• HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative.1 passage
• HIV infection is associated with thoracic and abdominal aortic aneurysms: a prospective matched cohort study.1 passage
• Haematological determinants of cardiac involvement in adults with sickle cell disease.1 passage
• Haeme oxygenase signalling pathway: implications for cardiovascular disease.1 passage
• Haemodynamic profiles of children with end-stage heart failure.1 passage
• Haemodynamic stress-induced breaches of the arterial intima trigger inflammation and drive atherogenesis.1 passage
• Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction.1 passage
• Happy heart syndrome: role of positive emotional stress in takotsubo syndrome.1 passage
• Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery.1 passage
• Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.1 passage
• Heart failure can affect everyone: the ESC Geoffrey Rose lecture.1 passage
• Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.1 passage
• Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.1 passage
• Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.1 passage
• Heart failure with preserved ejection fraction: from mechanisms to therapies.1 passage
• Heart failure: when form fails to follow function.1 passage
• Heart healthy cities: genetics loads the gun but the environment pulls the trigger.1 passage
• Heme oxygenase-1 suppresses a pro-inflammatory phenotype in monocytes and determines endothelial function and arterial hypertension in mice and humans.1 passage
• Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study.1 passage
• High blood pressure response to exercise predicts future development of hypertension in young athletes.1 passage
• High lipoprotein(a) and high risk of mortality.1 passage
• High penetrance and similar disease progression in probands and in family members with arrhythmogenic cardiomyopathy.1 passage
• High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events.1 passage
• High-intensity interval training modulates retinal microvascular phenotype and DNA methylation of p66Shc gene: a randomized controlled trial (EXAMIN AGE).1 passage
• High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study.1 passage
• High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population.1 passage
• High-sugar feeding and increasing cholesterol levels in infants.1 passage
• Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.1 passage
• Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help.1 passage
• Highly sensitive troponin and coronary computed tomography angiography in the evaluation of suspected acute coronary syndrome in the emergency department.1 passage
• Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium.1 passage
• Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.1 passage
• Hot stuff: a rare diagnosis of a mitral valve mass confirmed on cardiac fludeoxyglucose positron emission tomography.1 passage
• Hot topics and trends in cardiovascular research.1 passage
• How do we reduce embolic risk and mortality in infective endocarditis? Measure the size of the vegetation and operate early in patients with large vegetations.1 passage
• How does coronary stent implantation impact on the status of the microcirculation during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction?1 passage
• How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol.1 passage
• How robust are clinical trials in heart failure?1 passage
• How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).1 passage
• Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report.1 passage
• Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines.1 passage
• Hybrid intravascular imaging: recent advances, technical considerations, and current applications in the study of plaque pathophysiology.1 passage
• Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney.1 passage
• Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure.1 passage
• Hypertensive disorders of pregnancy and onset of chronic hypertension in France: the nationwide CONCEPTION study.1 passage
• Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers.1 passage
• IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-adrenergic insult.1 passage
• ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.1 passage
• Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model.1 passage
• Identification of capillary rarefaction using intracoronary wave intensity analysis with resultant prognostic implications for cardiac allograft patients.1 passage
• Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.1 passage
• Identifying patients with acute total coronary occlusion in NSTEACS: finding the high-risk needle in the haystack.1 passage
• Imaging atherosclerosis with positron emission tomography.1 passage
• Imaging of congenital heart disease in adults.1 passage
• Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance.1 passage
• Imaging residual inflammatory cardiovascular risk.1 passage
• Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study.1 passage
• Immediate post-procedural functional assessment of percutaneous coronary intervention: current evidence and future directions.1 passage
• Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia.1 passage
• Immunotherapy for cardiovascular disease.1 passage
• Impact of COVID-19 pandemic restrictions on ST-elevation myocardial infarction: a cardiac magnetic resonance imaging study.1 passage
• Impact of a public awareness campaign on out-of-hospital cardiac arrest incidence and mortality rates.1 passage
• Impact of active smoking on myocardial infarction severity in reperfused ST-segment elevation myocardial infarction patients: the smoker's paradox revisited.1 passage
• Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction.1 passage
• Impact of ambulatory cardiac rehabilitation on cardiovascular outcomes: a long-term follow-up study.1 passage
• Impact of bystander-initiated cardiopulmonary resuscitation for out-of-hospital cardiac arrest: where would you be happy to have a cardiac arrest?1 passage
• Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention.1 passage
• Impact of cholesterol on proinflammatory monocyte production by the bone marrow.1 passage
• Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women.1 passage
• Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.1 passage
• Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia.1 passage
• Impact of combined plaque structural stress and wall shear stress on coronary plaque progression, regression, and changes in composition.1 passage
• Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients.1 passage
• Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers.1 passage
• Impact of geographical origin upon the electrical and structural manifestations of the black athlete's heart.1 passage
• Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.1 passage
• Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction.1 passage
• Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.1 passage
• Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial.1 passage
• Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.1 passage
• Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.1 passage
• Impact of low stroke volume on mortality in patients with severe aortic stenosis and preserved left ventricular ejection fraction.1 passage
• Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis.1 passage
• Impact of preoperative fractional flow reserve on arterial bypass graft anastomotic function: the IMPAG trial.1 passage
• Impact of recurrent mitral regurgitation after mitral valve repair for functional mitral regurgitation: long-term analysis of competing outcomes.1 passage
• Impact of renin-angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries.1 passage
• Impact of sex on the management and outcome of aortic stenosis patients.1 passage
• Impact of sex on the management and outcome of aortic stenosis patients: a female aortic valve stenosis paradox, and a call for personalized treatments?1 passage
• Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials.1 passage
• Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis.1 passage
• Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial.1 passage
• Impaired baroreflex sensitivity, carotid stiffness, and exaggerated exercise blood pressure: a community-based analysis from the Paris Prospective Study III.1 passage
• Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study.1 passage
• Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry.1 passage
• Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials.1 passage
• Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis.1 passage
• Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest.1 passage
• Implementing the new European Regulations on medical devices-clinical responsibilities for evidence-based practice: a report from the Regulatory Affairs Committee of the European Society of Cardiology.1 passage
• Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease.1 passage
• Importance of functional food compounds in cardioprotection through action on the epigenome.1 passage
• Importance of sex and gender in ischaemic stroke and carotid atherosclerotic disease.1 passage
• Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention.1 passage
• Improved oral hygiene care attenuates the cardiovascular risk of oral health disease: a population-based study from Korea.1 passage
• Improved outcome in Sweden after out-of-hospital cardiac arrest and possible association with improvements in every link in the chain of survival.1 passage
• Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT.1 passage
• Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014.1 passage
• Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.1 passage
• Improving public health by improving clinical trial guidelines and their application.1 passage
• In vivo predictors of plaque erosion in patients with ST-segment elevation myocardial infarction: a clinical, angiographical, and intravascular optical coherence tomography study.1 passage
• In-hospital mortality of patients with atrial arrhythmias: insights from the German-wide Helios hospital network of 161 502 patients and 34 025 arrhythmia-related procedures.1 passage
• In-hospital resuscitation of Covid-19 patients is impeded by serious delays, but the problem is obscured by poor time data.1 passage
• In-stent restenosis following third-generation sirolimus-eluting stent implantation: first report analysed from imaging modalities and histopathological findings.1 passage
• Inappropriate inclusion of multiple studies in a meta-analysis of randomized controlled trials of atorvastatin loading prior to percutaneous coronary intervention for acute coronary syndrome.1 passage
• Incidence and factors associated with infective endocarditis in patients undergoing left-sided heart valve replacement.1 passage
• Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (TranscatheteR HeArt Valve EmboLization and Migration).1 passage
• Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI).1 passage
• Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1.1 passage
• Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014.1 passage
• Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982-2018).1 passage
• Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study.1 passage
• Incidence of infective endocarditis among patients considered at high risk.1 passage
• Incidence of infective endocarditis in patients considered at moderate risk.1 passage
• Incidence of ischaemic stroke and mortality in patients with acute coronary syndrome and first-time detected atrial fibrillation: a nationwide study.1 passage
• Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry.1 passage
• Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis.1 passage
• Incidence, risk factors, and predictors of infective endocarditis in adult congenital heart disease: focus on the use of prosthetic material.1 passage
• Inclusion of multiple inappropriate studies in a meta-analysis of randomized controlled trials of atorvastatin loading prior to percutaneous coronary intervention for acute coronary syndrome: editor's response.1 passage
• Increased absorption of phytosterols is the simplest and most plausible explanation for coronary artery disease risk not accounted for by non-HDL cholesterol in high cholesterol absorbers.1 passage
• Increased haematopoietic activity in patients with atherosclerosis.1 passage
• Increased risk of aortic valve stenosis in patients with psoriasis: a nationwide cohort study.1 passage
• Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark.1 passage
• Increasing population height and risk of incident atrial fibrillation: the Copenhagen City Heart Study.1 passage
• Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator.1 passage
• Incremental prognostic utility of coronary CT angiography for asymptomatic patients based upon extent and severity of coronary artery calcium: results from the COronary CT Angiography EvaluatioN For Clinical Outcomes InteRnational Multicenter (CONFIRM) study.1 passage
• Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.1 passage
• Indications and practical approach to non-invasive ventilation in acute heart failure.1 passage
• Induced pluripotent stem cells as a biopharmaceutical factory for extracellular vesicles.1 passage
• Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials.1 passage
• Infected cardiac-implantable electronic devices: prevention, diagnosis, and treatment.1 passage
• Infected left ventricular thrombus revealing an unrecognized coronary dissection after blunt chest trauma, treated with emergency heart transplantation.1 passage
• Infections, atherosclerosis, and coronary heart disease.1 passage
• Infective endocarditis after transcatheter aortic valve implantation: a nationwide study.1 passage
• Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease.1 passage
• Inflammatory cytokines in atherosclerosis: current therapeutic approaches.1 passage
• Influence of coronary vessel dominance on short- and long-term outcome in patients after ST-segment elevation myocardial infarction.1 passage
• Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.1 passage
• Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.1 passage
• Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.1 passage
• Influenza vaccination: a 'shot' at INVESTing in cardiovascular health.1 passage
• Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2.1 passage
• Innate immune cells in ischaemic heart disease: does myocardial infarction beget myocardial infarction?1 passage
• Insights into sudden cardiac death: exploring the potential relevance of non-diagnostic autopsy findings.1 passage
• Insomnia symptoms and incident heart failure: a population-based cohort study.1 passage
• Integrated imaging of echocardiography and computed tomography to grade mitral regurgitation severity in patients undergoing transcatheter aortic valve implantation.1 passage
• Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial.1 passage
• Integration of transthoracic focused cardiac ultrasound in the diagnostic algorithm for suspected acute aortic syndromes.1 passage
• Intentional transcatheter laceration of the coronary cusp to prevent left main stem obstruction during transcatheter aortic valve implantation: first European experience with the BASILICA technique in a native aortic valve.1 passage
• Inter-ethnic differences in valve morphology, valvular dysfunction, and aortopathy between Asian and European patients with bicuspid aortic valve.1 passage
• Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment. Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention.1 passage
• Interleukin-1 blockade in cardiovascular diseases: a clinical update.1 passage
• International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology.1 passage
• International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management.1 passage
• International recommendations for electrocardiographic interpretation in athletes.1 passage
• International standardization of diagnostic criteria for vasospastic angina.1 passage
• Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.1 passage
• Interventional cardiology, where real life and science do not necessarily meet.1 passage
• Interventional procedures and future drug therapy for hypertension.1 passage
• Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure.1 passage
• Intimal lesions detected by optical coherence tomography herald intraluminal progression of cardiac allograft vasculopathy associated with humoral rejection.1 passage
• Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines.1 passage
• Intra-operative defibrillation testing and clinical shock efficacy in patients with implantable cardioverter-defibrillators: the NORDIC ICD randomized clinical trial.1 passage
• Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial.1 passage
• Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial.1 passage
• Intracoronary dual-modal optical coherence tomography-near-infrared fluorescence structural-molecular imaging with a clinical dose of indocyanine green for the assessment of high-risk plaques and stent-associated inflammation in a beating coronary artery.1 passage
• Intracoronary imaging identifies plaque rupture underlying left main thrombosis in acute myocardial infarction without angiographically evident atherosclerosis.1 passage
• Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment.1 passage
• Intravascular ultrasound-guided management of ST-elevation myocardial infarction in a patient with lung cancer and myocardial metastasis.1 passage
• Invasive and non-invasive assessment of ischaemia in chronic coronary syndromes: translating pathophysiology to clinical practice.1 passage
• Invasive coronary imaging: any role in primary and secondary prevention?1 passage
• Invasive left ventricle pressure-volume analysis: overview and practical clinical implications.1 passage
• Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.1 passage
• Iron alters valvular interstitial cell function and is associated with calcification in aortic stenosis.1 passage
• Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.1 passage
• Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.1 passage
• Is the national readmission database the right database to identify valve-in-valve transcatheter aortic valve replacement patients?1 passage
• Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?1 passage
• Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.1 passage
• Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.1 passage
• Ischaemic stroke and ST-segment elevation myocardial infarction: fast-track single-stop approach.1 passage
• Isolated cardiac sarcoidosis: the crucial role of multimodal imaging with positron emission tomography/magnetic resonance imaging in diagnosis and therapy surveillance.1 passage
• Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes.1 passage
• Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome.1 passage
• Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank.1 passage
• Korean atrial fibrillation network genome-wide association study for early-onset atrial fibrillation identifies novel susceptibility loci.1 passage
• LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS project.1 passage
• Lack of specialist care is associated with increased morbidity and mortality in adult congenital heart disease: a population-based study.1 passage
• Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation.1 passage
• Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study.1 passage
• Late cardiac erosion after percutaneous ventricular septal defect closure: a complication after ventricular septal defect device implantation.1 passage
• Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials.1 passage
• Leaders in Cardiovascular Medicine. Eugene Braunwald MD: an icon of the 20th century still going strong.1 passage
• Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up.1 passage
• Leaflet immobility and thrombosis in transcatheter aortic valve replacement.1 passage
• Lean body mass and risk of incident atrial fibrillation in post-menopausal women.1 passage
• Learning whether to subtract beta-blockers: it's about time.1 passage
• Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease.1 passage
• Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study.1 passage
• Left atrial appendage occlusion: rationale, evidence, devices, and patient selection.1 passage
• Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value.1 passage
• Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry.1 passage
• Left ventricular assist devices: current controversies and future directions.1 passage
• Left ventricular heart failure and pulmonary hypertension.1 passage
• Left ventricular systolic function assessment in secondary mitral regurgitation: left ventricular ejection fraction vs. speckle tracking global longitudinal strain.1 passage
• Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study.1 passage
• Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation.1 passage
• Less dementia with oral anticoagulation in atrial fibrillation.1 passage
• Lesson learnt from the new 2020 ESC guidelines on non-ST-segment elevation acute coronary syndrome: when clinical judgement precedes and overpasses weak recommendations. 2020 non-ST-segment elevation acute coronary syndrome guidelines on pre-treatment: primum non nocere!1 passage
• Lethal enterovirus myocarditis in a patient with granulomatosis with polyangiitis following rituximab and high-dose steroid therapy.1 passage
• Leucocyte immunoglobulin-like receptor subfamily-B5 (LILRB5) genetic variation and statin-associated muscle symptoms: another piece in a puzzling puzzle.1 passage
• Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.1 passage
• Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study.1 passage
• Lifetime risk: childhood obesity and cardiovascular risk.1 passage
• Limited reproducibility of MUCH and WUCH: evidence from the ELSA study.1 passage
• Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.1 passage
• Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study.1 passage
• Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.1 passage
• Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia.1 passage
• Lipoprotein(a): the revenant.1 passage
• Lipoproteins in chronic kidney disease: from bench to bedside.1 passage
• Live-case demonstrations: putting patients first.1 passage
• Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals.1 passage
• Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?1 passage
• Living myocardial slices: a novel multicellular model for cardiac translational research.1 passage
• Long term trends in natriuretic peptide testing for heart failure in UK primary care: a cohort study.1 passage
• Long working hours as a risk factor for atrial fibrillation: a multi-cohort study.1 passage
• Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Tromsø Study.1 passage
• Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases.1 passage
• Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease.1 passage
• Long-term cardiovascular disease mortality among 160 834 5-year survivors of adolescent and young adult cancer: an American population-based cohort study.1 passage
• Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population.1 passage
• Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry.1 passage
• Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis.1 passage
• Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial.1 passage
• Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.1 passage
• Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.1 passage
• Long-term exposure to ambient air pollution and traffic noise and incident hypertension in seven cohorts of the European study of cohorts for air pollution effects (ESCAPE).1 passage
• Long-term exposure to road traffic noise, ambient air pollution, and cardiovascular risk factors in the HUNT and lifelines cohorts.1 passage
• Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.1 passage
• Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II.1 passage
• Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study.1 passage
• Long-term mortality in patients with atrial septal defect: a nationwide cohort-study.1 passage
• Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).1 passage
• Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.1 passage
• Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study.1 passage
• Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves.1 passage
• Long-term outcomes following endovascular and surgical revascularization for peripheral artery disease: a propensity score-matched analysis.1 passage
• Long-term outcomes in young patients with atrioventricular block of unknown aetiology.1 passage
• Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry.1 passage
• Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality.1 passage
• Long-term survival and causes of death in patients with ST-elevation acute coronary syndrome without obstructive coronary artery disease.1 passage
• Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry.1 passage
• Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.1 passage
• Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.1 passage
• Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure.1 passage
• Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.1 passage
• Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy.1 passage
• Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry.1 passage
• Low coronary flow relative to myocardial mass predicts heart failure in symptomatic hypertensive patients with no obstructive coronary artery disease.1 passage
• Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study.1 passage
• Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial.1 passage
• Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study.1 passage
• Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.1 passage
• Low-density lipoprotein particle diameter and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.1 passage
• Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.1 passage
• Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.1 passage
• Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.1 passage
• Low-grade endotoxaemia enhances artery thrombus growth via Toll-like receptor 4: implication for myocardial infarction.1 passage
• Low-gradient aortic stenosis.1 passage
• Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies.1 passage
• Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study.1 passage
• Lowering cholesterol in chronic kidney disease: is it safe and effective?1 passage
• Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.1 passage
• MR assessment of a post-traumatic ventricular septum defect using 4D flow in a patient with multiple knife-related injuries.1 passage
• Machine learning algorithms estimating prognosis and guiding therapy in adult congenital heart disease: data from a single tertiary centre including 10 019 patients.1 passage
• Machine learning for prediction of all-cause mortality in patients with suspected coronary artery disease: a 5-year multicentre prospective registry analysis.1 passage
• Machine learning of clinical variables and coronary artery calcium scoring for the prediction of obstructive coronary artery disease on coronary computed tomography angiography: analysis from the CONFIRM registry.1 passage
• Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score.1 passage
• Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPARγ signature.1 passage
• Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome.1 passage
• Magnetic resonance imaging safety in pacemaker and implantable cardioverter defibrillator patients: how far have we come?1 passage
• Mammographic features are associated with cardiometabolic disease risk and mortality.1 passage
• Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction.1 passage
• Management errors in adults with congenital heart disease: prevalence, sources, and consequences.1 passage
• Management of acute cardiovascular complications in pregnancy.1 passage
• Management of acute coronary syndromes in older adults.1 passage
• Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation - Dual versus triple antithrombotic therapy.1 passage
• Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.1 passage
• Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease.1 passage
• Management of cardiogenic shock complicating myocardial infarction: an update 2019.1 passage
• Management of cardiogenic shock.1 passage
• Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on 'Dapagliflozin in Patients with Chronic Kidney Disease'.1 passage
• Management of ischaemic stroke, prognostic impact of procedural myocardial injury, and antiplatelet treatment: the many facets of interventional cardiology.1 passage
• Management of left main disease: an update.1 passage
• Management of non-culprit coronary plaques in patients with acute coronary syndrome.1 passage
• Management of refractory angina: an update.1 passage
• Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves.1 passage
• Management of valvular disease in pregnancy: a global perspective.1 passage
• Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions.1 passage
• Managing patients with ST-elevation myocardial infarction and multivessel disease: is the story complete?1 passage
• Mapping cross-border collaboration and communication in cardiovascular research from 1992 to 2012.1 passage
• Mapping interventional cardiology in Europe: the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Atlas Project.1 passage
• Marfan Sartan: a randomized, double-blind, placebo-controlled trial.1 passage
• Markers of kidney tubule function and risk of cardiovascular disease events and mortality in the SPRINT trial.1 passage
• Masked hypertension: understanding its complexity.1 passage
• Maternal and neonatal complications in women with congenital heart disease: a nationwide analysis.1 passage
• Matrix metalloproteinase-2 on activated platelets triggers endothelial PAR-1 initiating atherosclerosis.1 passage
• Matrix metalloproteinase-9 might affect adaptive immunity in non-ST segment elevation acute coronary syndromes by increasing CD31 cleavage on CD4+ T-cells.1 passage
• Maximum-fixed energy shocks for cardioverting atrial fibrillation.1 passage
• May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension.1 passage
• Mechanical aortic valve replacement in non-elderly adults: meta-analysis and microsimulation.1 passage
• Mechanical versus bioprosthetic aortic valve replacement.1 passage
• Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization.1 passage
• Mechanisms linking preterm birth to onset of cardiovascular disease later in adulthood.1 passage
• Mechanisms of heart failure with preserved ejection fraction, risk stratification of heart failure with reduced ejection fraction, and new light on resistance to diuretics in acute decompensated heart failure.1 passage
• Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry.1 passage
• Medical three-dimensional printing opens up new opportunities in cardiology and cardiac surgery.1 passage
• Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease.1 passage
• Mendelian randomization of blood lipids for coronary heart disease.1 passage
• Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis.1 passage
• Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study.1 passage
• Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation.1 passage
• Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study.1 passage
• Mitral valve surgery after MitraClip® implantation: what histopathology can tell us?1 passage
• Mixed aortic valve disease: midterm outcome and predictors of adverse events.1 passage
• Mixed reality navigation of a systemic venous baffle obstruction: unravelling the percutaneous approach in atrial switch operation.1 passage
• Mobile health technology facilitates population screening and integrated care management in patients with atrial fibrillation.1 passage
• Mobile technology and the digitization of healthcare.1 passage
• Mode-of-action of the PROPELLA concept in fulminant myocarditis.1 passage
• Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.1 passage
• Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials.1 passage
• Modifier genes for sudden cardiac death.1 passage
• Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).1 passage
• Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4.1 passage
• Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease.1 passage
• Molecular signature of cardiogenic shock.1 passage
• Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases.1 passage
• Mononuclear cell secretome protects from experimental autoimmune myocarditis.1 passage
• Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.1 passage
• Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials.1 passage
• Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis.1 passage
• Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.1 passage
• Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial.1 passage
• Mortality reduction with physical activity in patients with and without cardiovascular disease.1 passage
• Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges.1 passage
• Multi-vessel revascularization in ST-segment elevation myocardial infarction: where do we stand?1 passage
• Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial.1 passage
• Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study).1 passage
• Multimodality imaging in valvular heart disease: how to use state-of-the-art technology in daily practice.1 passage
• Music and the heart.1 passage
• Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region.1 passage
• Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.1 passage
• Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a survival benefit from early revascularization.1 passage
• Myocardial blush and microvascular reperfusion following manual thrombectomy during percutaneous coronary intervention for ST elevation myocardial infarction: insights from the TOTAL trial.1 passage
• Myocardial hypoxic stress mediates functional cardiac extracellular vesicle release.1 passage
• Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population.1 passage
• Myocardial injury after non-cardiac surgery: diagnosis and management.1 passage
• Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial.1 passage
• Myocardial strain imaging: how useful is it in clinical decision making?1 passage
• Myocardial viability testing: all STICHed up, or about to be REVIVED?1 passage
• Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome.1 passage
• N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.1 passage
• Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves.1 passage
• Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up.1 passage
• Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study.1 passage
• Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment.1 passage
• Neochord anterior leaflet treatment to facilitate transcatheter mitral valve replacement with 3D real-time echocardiography.1 passage
• Neuraminidase 1 is a driver of experimental cardiac hypertrophy.1 passage
• Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction.1 passage
• New challenges in vascular biology and medicine: from unravelling the mechanisms of neointima formation to the prevention of amputations and of ischaemic stroke.1 passage
• New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease.1 passage
• New guidelines on adult congenital heart disease, the fantastic four in the treatment of heart failure, and also what happened in the last year in heart failure and valvular heart disease.1 passage
• New insights into mitral valve dystrophy: a Filamin-A genotype-phenotype and outcome study.1 passage
• New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people.1 passage
• New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial.1 passage
• News from TCT San Diego 2018: Intracoronary Imaging: New evidence on optimization of stent implantation and detection of patients and vessels at risk presented at Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San Diego.1 passage
• Nitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial.1 passage
• No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.1 passage
• No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.1 passage
• Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients.1 passage
• Nomenclature for kidney function and disease-executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference.1 passage
• Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.1 passage
• Non-invasive imaging of the coronary arteries.1 passage
• Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk.1 passage
• Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men.1 passage
• Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.1 passage
• Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions.1 passage
• Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.1 passage
• Novel endotypes in heart failure: effects on guideline-directed medical therapy.1 passage
• Novel mechanisms in the pathogenesis of atrial fibrillation: practical applications.1 passage
• Novel methodologies for biomarker discovery in atherosclerosis.1 passage
• Nurse-led vs. usual-care for atrial fibrillation.1 passage
• ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.1 passage
• Obesity and cardiovascular disease: friend or foe?1 passage
• Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.1 passage
• Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial.1 passage
• Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy.1 passage
• Office blood pressure or ambulatory blood pressure for the prediction of cardiovascular events.1 passage
• Omics phenotyping in heart failure: the next frontier.1 passage
• One in four major ischaemic heart disease events are fatal and 60% are pre-hospital deaths: a national data-linkage study (ANZACS-QI 8).1 passage
• One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry.1 passage
• One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study.1 passage
• Operator volume is not associated with mortality following percutaneous coronary intervention: insights from the British Cardiovascular Intervention Society registry.1 passage
• Optical coherence tomography follow-up after bioresorbable in metallic and metallic in bioresorbable stenting: tackling in-stent restenosis in the era of bioresorbable vascular scaffolds.1 passage
• Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study.1 passage
• Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): one-year angiographic and clinical results.1 passage
• Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence.1 passage
• Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society.1 passage
• Optimizing management of atrial fibrillation: integrated care, blood pressure control, ablation, and left atrial appendix occlusion.1 passage
• Optimizing percutaneous coronary interventions: Heart Team, SYNTAX II Score, physiology and imaging guidance, modern stents, and guideline-based medication.1 passage
• Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study.1 passage
• Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark.1 passage
• Oral dual antiplatelet therapy: what have we learnt from recent trials?1 passage
• Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control study.1 passage
• Orthostatic hypotension and symptomatic subclinical orthostatic hypotension increase risk of cognitive impairment: an integrated evidence review and analysis of a large older adult hypertensive cohort.1 passage
• Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis.1 passage
• Otto Klein from Prague University Hospital performed the world first diagnostic cardiac catheterization in 11 Czech patients in 1929.1 passage
• Out-of-Hospital Cardiac Arrest: Handle With Care-Comment on the Resuscitation Outcomes Consortium Cardiac Epidemiologic Registry.1 passage
• Outcome after transvascular transcatheter aortic valve implantation in 2016.1 passage
• Outcome in middle-aged individuals with anomalous origin of the coronary artery from the opposite sinus: a matched cohort study.1 passage
• Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: a multicentre series of 52 cases.1 passage
• Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation.1 passage
• Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.1 passage
• Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification.1 passage
• Outcomes of transfemoral transcatheter aortic valve implantation at hospitals with and without on-site cardiac surgery department: insights from the prospective German aortic valve replacement quality assurance registry (AQUA) in 17 919 patients.1 passage
• Outdoor light at night and risk of coronary heart disease among older adults: a prospective cohort study.1 passage
• Outdoor temperature, blood pressure, and cardiovascular disease mortality among 23 000 individuals with diagnosed cardiovascular diseases from China.1 passage
• Overall and abdominal obesity and incident aortic valve stenosis: two prospective cohort studies.1 passage
• Oxygen therapy in ST-elevation myocardial infarction.1 passage
• PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.1 passage
• PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia.1 passage
• Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review.1 passage
• Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study).1 passage
• Paradoxical impact of socioeconomic factors on outcome of atrial fibrillation in Europe: trends in incidence and mortality from atrial fibrillation.1 passage
• Paravalvular leakage due to ring dehiscence after mitral valve-in-ring therapy: mechanisms and percutaneous treatment.1 passage
• Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes.1 passage
• Past and current cause-specific mortality in Eisenmenger syndrome.1 passage
• Patent foramen ovale and long-term risk of ischaemic stroke after surgery.1 passage
• Patent foramen ovale closure for secondary stroke prevention.1 passage
• Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials.1 passage
• Pathologic T-cell response in ischaemic failing hearts elucidated by T-cell receptor sequencing and phenotypic characterization.1 passage
• Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study.1 passage
• Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction.1 passage
• Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications.1 passage
• Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments.1 passage
• Patient-tailored antithrombotic therapy following percutaneous coronary intervention.1 passage
• Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY).1 passage
• Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests.1 passage
• Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death.1 passage
• Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance.1 passage
• Peak oxygen uptake and incident coronary heart disease in a healthy population: the HUNT Fitness Study.1 passage
• Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.1 passage
• Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial.1 passage
• Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.1 passage
• Percutaneous closure of patent foramen ovale: an underutilized prevention?1 passage
• Percutaneous closure of right coronary artery to the left ventricle coronary cameral fistula in a case of congenitally absent left coronary artery.1 passage
• Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States.1 passage
• Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA.1 passage
• Percutaneous paravalvular leak closure: chasing the chameleon.1 passage
• Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials.1 passage
• Percutaneous treatment of severe transvalvular and paravalvular regurgitation in a failing surgical aortic valve prosthesis due to recurrent endocarditis.1 passage
• Percutaneous tricuspid valve therapies: the new frontier.1 passage
• Performance of hospitals according to the ESC ACCA quality indicators and 30-day mortality for acute myocardial infarction: national cohort study using the United Kingdom Myocardial Ischaemia National Audit Project (MINAP) register.1 passage
• Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction.1 passage
• Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction.1 passage
• Perioperative acute myocardial infarction associated with non-cardiac surgery.1 passage
• Peripartum cardiomyopathy: current management and future perspectives.1 passage
• Peripartum cardiomyopathy: from genetics to management.1 passage
• Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence.1 passage
• Periprocedural myocardial infarction and injury in elective coronary stenting.1 passage
• Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.1 passage
• Persisting burden and challenges of rheumatic heart disease.1 passage
• Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors.1 passage
• Personalized exercise dose prescription.1 passage
• Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.1 passage
• Pharmacological therapy in adult congenital heart disease: growing need, yet limited evidence.1 passage
• Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences.1 passage
• Physical activity, cardiorespiratory fitness, and cardiovascular outcomes in individuals with atrial fibrillation: the HUNT study.1 passage
• Physical activity, resting heart rate, and atrial fibrillation: the Tromsø Study.1 passage
• Plans of the British Cardiovascular Society to seek patients' views on research may aid research grant applications.1 passage
• Plaque erosion: a new in vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes.1 passage
• Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome.1 passage
• Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.1 passage
• Plasma concentration of serotonin is a novel biomarker for coronary microvascular dysfunction in patients with suspected angina and unobstructive coronary arteries.1 passage
• Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort.1 passage
• Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study.1 passage
• Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.1 passage
• Plasma soluble neprilysin levels are unchanged during recovery after decompensation of heart failure: a matter of the magnitude of the changes in systemic haemodynamics?1 passage
• Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.1 passage
• Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.1 passage
• Pleiotropic effects of laminar flow and statins depend on the Krüppel-like factor-induced lncRNA MANTIS.1 passage
• Polymorphic ventricular tachycardia, ischaemic ventricular fibrillation, and torsade de pointes: importance of the QT and the coupling interval in the differential diagnosis.1 passage
• Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.1 passage
• Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.1 passage
• Possible early recoil phenomenon in a self-expandable transcatheter bioprosthesis compressed by a huge annular calcification.1 passage
• Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke.1 passage
• Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR).1 passage
• Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).1 passage
• Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome.1 passage
• Potential effects of time-varying characteristics and discrepancies in covariates distribution upon interpreting the results from the association of air pollution and physical activity with cardiovascular disease among young adults.1 passage
• Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry.1 passage
• Pre-term delivery and long-term risk of heart failure in women: a national cohort and co-sibling study.1 passage
• Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?1 passage
• Precision Medicine and cardiac channelopathies: when dreams meet reality.1 passage
• Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score.1 passage
• Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores.1 passage
• Predicting sudden cardiac death using common genetic risk variants for coronary artery disease.1 passage
• Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score.1 passage
• Predicting the development of in-hospital cardiogenic shock in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: the ORBI risk score.1 passage
• Prediction of adverse events after catheter-based procedures in adolescents and adults with congenital heart disease in the IMPACT registry.1 passage
• Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.1 passage
• Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people.1 passage
• Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina.1 passage
• Prediction of sudden and non-sudden cardiac death in post-infarction patients with reduced left ventricular ejection fraction by periodic repolarization dynamics: MADIT-II substudy.1 passage
• Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction.1 passage
• Prediction, staging, and outcomes of ischaemic cardiogenic shock after STEMI: a complex clinical interplay.1 passage
• Predictive value of telomere length on outcome following acute myocardial infarction: evidence for contrasting effects of vascular vs. blood oxidative stress.1 passage
• Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.1 passage
• Predictors of long-term mortality among perioperative survivors of Fontan operation.1 passage
• Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score.1 passage
• Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study.1 passage
• Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study.1 passage
• Pregnancy in women with congenital heart disease.1 passage
• Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC).1 passage
• Pregnancy loss and risk of cardiovascular disease: the Nurses' Health Study II.1 passage
• Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC).1 passage
• Pregnancy-associated arterial dissections: a nationwide cohort study.1 passage
• Preoperative thresholds for mid-to-late haemodynamic and clinical outcomes after pulmonary valve replacement in tetralogy of Fallot.1 passage
• Presentation blood glucose and death, hospitalization, and future diabetes risk in patients with acute heart failure syndromes.1 passage
• Pressure gradient vs. flow relationships to characterize the physiology of a severely stenotic aortic valve before and after transcatheter valve implantation.1 passage
• Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.1 passage
• Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness.1 passage
• Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.1 passage
• Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.1 passage
• Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation.1 passage
• Prevalence and prognosis of ischaemic and non-ischaemic myocardial fibrosis in older adults.1 passage
• Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study.1 passage
• Prevalence, incidence, and outcomes across cardiovascular diseases in homeless individuals using national linked electronic health records.1 passage
• Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients.1 passage
• Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock.1 passage
• Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin.1 passage
• Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype.1 passage
• Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.1 passage
• Prevention of cardiovascular diseases and dementia: the emerging role of air pollution, socioeconomic factors, e-cigarettes, new biomarkers, proteomics, and genetics.1 passage
• Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade.1 passage
• Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge.1 passage
• Primary care heart failure service identifies a missed cohort of heart failure patients with reduced ejection fraction.1 passage
• Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy.1 passage
• Probability of diagnosing long QT syndrome in children and adolescents according to the criteria of the HRS/EHRA/APHRS expert consensus statement.1 passage
• Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data.1 passage
• Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction.1 passage
• Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.1 passage
• Prognostic assessment of stable coronary artery disease as determined by coronary computed tomography angiography: a Danish multicentre cohort study.1 passage
• Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association.1 passage
• Prognostic impact of supraventricular premature complexes in community-based health checkups: the Ibaraki Prefectural Health Study.1 passage
• Prognostic impacts of Rho-kinase activity in circulating leucocytes in patients with vasospastic angina.1 passage
• Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.1 passage
• Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.1 passage
• Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.1 passage
• Prognostic importance of the transmitral pressure gradient in mitral annular calcification with associated mitral valve dysfunction.1 passage
• Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting.1 passage
• Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors.1 passage
• Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project.1 passage
• Prognostic value of PCSK9 levels in patients with acute coronary syndromes.1 passage
• Prognostic value of comprehensive intracoronary physiology assessment early after heart transplantation.1 passage
• Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study.1 passage
• Prognostic value of peak stress cardiac power in patients with normal ejection fraction undergoing exercise stress echocardiography.1 passage
• Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis.1 passage
• Prognostic value of stress echocardiography assessed by the ABCDE protocol.1 passage
• Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI).1 passage
• Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step back.1 passage
• Progression of artery aneurysm after transcatheter closure of coronary artery fistula.1 passage
• Progression of ultrasound plaque attenuation and low echogenicity associates with major adverse cardiovascular events.1 passage
• Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism.1 passage
• Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases.1 passage
• Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative.1 passage
• Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank.1 passage
• Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial).1 passage
• Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.1 passage
• Prostaglandin F2α formation is associated with mortality in a Swedish community-based cohort of older males.1 passage
• Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction.1 passage
• Protective effects of sirtuins in cardiovascular diseases: from bench to bedside.1 passage
• Protein-based cardiogenic shock patient classifier.1 passage
• Proximal aorta longitudinal strain predicts aortic root dilation rate and aortic events in Marfan syndrome.1 passage
• PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial.1 passage
• Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease.1 passage
• Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.1 passage
• Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome.1 passage
• Pulmonary embolism, COVID, and bleeding risk in acute coronary syndromes: a Focus Issue on thrombosis and antithrombotic treatment.1 passage
• Pulsatile arterial haemodynamics in heart failure.1 passage
• Quantifying infective endocarditis risk in patients with predisposing cardiac conditions.1 passage
• Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTE-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.1 passage
• Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Endorsed by: the European Stroke Organisation (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Soci1 passage
• Questions and answers on workup diagnosis and risk stratification: a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.1 passage
• RRAD mutation causes electrical and cytoskeletal defects in cardiomyocytes derived from a familial case of Brugada syndrome.1 passage
• Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation.1 passage
• Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.1 passage
• Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices.1 passage
• Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial.1 passage
• Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).1 passage
• Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial.1 passage
• Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis.1 passage
• Ranking of psychosocial and traditional risk factors by importance for coronary heart disease: the Copenhagen City Heart Study.1 passage
• Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease.1 passage
• Rare genetic variants previously associated with congenital forms of long QT syndrome have little or no effect on the QT interval.1 passage
• Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis.1 passage
• Rates and predictors of hospital readmission after transcatheter aortic valve implantation.1 passage
• Ratio of transmitral early filling velocity to early diastolic strain rate predicts long-term risk of cardiovascular morbidity and mortality in the general population.1 passage
• Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry.1 passage
• Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?1 passage
• Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies.1 passage
• Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients.1 passage
• Recommendations for advance care planning in adults with congenital heart disease: a position paper from the ESC Working Group of Adult Congenital Heart Disease, the Association of Cardiovascular Nursing and Allied Professions (ACNAP), the European Association for Palliative Care (EAPC), and the International Society for Adult Congenital Heart Disease (ISACHD).1 passage
• Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC).1 passage
• Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the European Association of Preventive Cardiology (EAPC), the European Society of Cardiology (ESC) Working Group on Adult Congenital Heart Disease and the Sports Cardiology, Physical Activity and Prevention Working Group of the Association for European Paediatric and Congenital Cardiology1 passage
• Recommendations for participation in competitive sport in athletes with hypertrophic cardiomyopathy: opening the sacks of Aeolus.1 passage
• Recommendations for participation in competitive sports of athletes with arterial hypertension: a position statement from the sports cardiology section of the European Association of Preventive Cardiology (EAPC).1 passage
• Recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC).1 passage
• Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version.1 passage
• Reconsidering the cut-off diastolic blood pressure for predicting cardiovascular events: a nationwide population-based study from Korea.1 passage
• Redox biomarkers in cardiovascular medicine.1 passage
• Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.1 passage
• Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry.1 passage
• Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction.1 passage
• Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.1 passage
• Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT angIOgraphy iN daily practice in 2017 (PROTECTION VI).1 passage
• Reduction of LDL-C-related residual cardiovascular risk with ezetimibe: are mechanistic considerations warranted in practice?1 passage
• Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials.1 passage
• Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era.1 passage
• Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.1 passage
• Refining the prognostic impact of functional mitral regurgitation in chronic heart failure.1 passage
• Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry.1 passage
• Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.1 passage
• Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction.1 passage
• Registry on acute cardiovascular events during endurance running races: the prospective RACE Paris registry.1 passage
• Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic?1 passage
• Regulation of oxidized platelet lipidome: implications for coronary artery disease.1 passage
• Reinnervation post-heart transplantation.1 passage
• Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014.1 passage
• Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.1 passage
• Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study.1 passage
• Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.1 passage
• Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials.1 passage
• Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis.1 passage
• Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.1 passage
• Remote management of heart failure using implantable electronic devices.1 passage
• Renal sodium avidity in heart failure: from pathophysiology to treatment strategies.1 passage
• Reperfusion delay in patients with high-risk ST-segment elevation myocardial infarction: every minute counts, much more than suspected.1 passage
• Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology.1 passage
• Replacing sitting time with standing or stepping: associations with cardio-metabolic risk biomarkers.1 passage
• Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.1 passage
• Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.1 passage
• Reply to letter by Frey et al. regarding the article: Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar.1 passage
• Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary.1 passage
• Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary.1 passage
• Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells.1 passage
• Rescue alcohol septal ablation for dynamic left ventricular outflow tract obstruction and haemodynamic collapse after transcatheter aortic valve implantation.1 passage
• Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions.1 passage
• Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.1 passage
• Resistant hypertension: what the cardiologist needs to know.1 passage
• Response to 'Detecting right ventricular dysfunction in patients diagnosed with low-risk pulmonary embolism: is routine computed tomographic pulmonary angiography sufficient?'1 passage
• Response to 'The potential multiple effects of beta3-adrenergic receptor agonists on the heart protection for patients with heart failure with preserved ejection fraction'.1 passage
• Response to Commentary for 'Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials'.1 passage
• Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials.1 passage
• Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: a meta-analysis.1 passage
• Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study.1 passage
• Retinal microvascular dysfunction in heart failure.1 passage
• Revascularization in stable coronary artery disease: a combined perspective from an interventional cardiologist and a cardiac surgeon.1 passage
• Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis.1 passage
• Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study.1 passage
• Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome.1 passage
• Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data.1 passage
• Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis.1 passage
• Right ventricle dysfunction in patients with acute pulmonary embolism supposedly at low risk for death: when evidence-based medicine rescues clinical practice.1 passage
• Risk factor exposure in individuals free from cardiovascular disease differs according to age at first myocardial infarction.1 passage
• Risk factors for excess mortality in adults with congenital heart diseases.1 passage
• Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort.1 passage
• Risk factors for type 1 and type 2 myocardial infarction.1 passage
• Risk for hypertension crosses generations in the community: a multi-generational cohort study.1 passage
• Risk model for estimating the 1-year risk of deferred lesion intervention following deferred revascularization after fractional flow reserve assessment.1 passage
• Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort.1 passage
• Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.1 passage
• Risk of hypertension into adulthood in persons born prematurely: a national cohort study.1 passage
• Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.1 passage
• Risk of sports-related sudden cardiac death in women.1 passage
• Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery.1 passage
• Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.1 passage
• Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study.1 passage
• Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history.1 passage
• Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort.1 passage
• Risk stratification and treatment of acute and chronic coronary syndromes: focus on angina without obstructive coronary arteries, refractory angina, lipids, and clonal haematopoiesis.1 passage
• Risk stratification for stroke in atrial fibrillation: a critique.1 passage
• Risk stratification in acute myocardial infarction with multiparametric cardiac magnetic resonance imaging: getting to the core of the matter.1 passage
• Risk stratification of patients undergoing medical therapy after coronary angiography.1 passage
• Risk stratification refinement and implantable cardioverter defibrillator protection for the coronary artery disease patients with a preserved left ventricular systolic function with a two-step programmed ventricular stimulation-inclusive approach.1 passage
• Road traffic noise and cardiovascular disease risk factors in UK Biobank.1 passage
• Road traffic noise is associated with increased cardiovascular morbidity and mortality and all-cause mortality in London.1 passage
• Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future.1 passage
• Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome.1 passage
• Role of T-cells in myocardial infarction.1 passage
• Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.1 passage
• Roles of exosomes in cardioprotection.1 passage
• Rosuvastatin use improves measures of coagulation in patients with venous thrombosis.1 passage
• Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?1 passage
• Running in polluted air is a two-edged sword - physical exercise in low air pollution areas is cardioprotective but detrimental for the heart in high air pollution areas.1 passage
• SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups.1 passage
• SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.1 passage
• SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions.1 passage
• SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.1 passage
• SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve.1 passage
• Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.1 passage
• Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study.1 passage
• Safety and efficacy of a repositionable and fully retrievable aortic valve used in routine clinical practice: the RESPOND Study.1 passage
• Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.1 passage
• Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.1 passage
• Safety and efficiency of a common and simplified protocol for pacemaker and defibrillator surveillance based on remote monitoring only: a long-term randomized trial (RM-ALONE).1 passage
• Safety of mechanical chest compression devices AutoPulse and LUCAS in cardiac arrest: a randomized clinical trial for non-inferiority.1 passage
• Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake.1 passage
• Salt reduction to prevent hypertension: the reasons of the controversy.1 passage
• Screening for atrial fibrillation: a call for evidence.1 passage
• Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology.1 passage
• Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry.1 passage
• Secondary tricuspid regurgitation in patients with left ventricular systolic dysfunction: cause for concern or innocent bystander?1 passage
• Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction.1 passage
• Seeing the unseen: post-infarction inflammation in an isolated right ventricular myocardial infarction visualized by combined cardiac magnetic resonance imaging and chemokine receptor CXCR4-targeted molecular imaging.1 passage
• Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia.1 passage
• Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis.1 passage
• Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis.1 passage
• Serial 18F-fluorodeoxyglucose positron emission tomography/CT angiography in transcatheter-implanted aortic valve endocarditis.1 passage
• Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.1 passage
• Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk.1 passage
• Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease.1 passage
• Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.1 passage
• Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome.1 passage
• Sex associations and computed tomography coronary angiography-guided management in patients with stable chest pain.1 passage
• Sex differences and temporal trends in aortic dissection: a population-based study of incidence, treatment strategies, and outcome in Swedish patients during 15 years.1 passage
• Sex differences in calcified plaque and long-term cardiovascular mortality: observations from the CAC Consortium.1 passage
• Sex differences in heart failure.1 passage
• Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data.1 passage
• Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome.1 passage
• Sex-based differences in outcomes, 30-day readmissions, and costs following catheter ablation of atrial fibrillation: the United States Nationwide Readmissions Database 2010-14.1 passage
• Sex-related differences in calcific aortic stenosis: correlating clinical and echocardiographic characteristics and computed tomography aortic valve calcium score to excised aortic valve weight.1 passage
• Sex-related trends in mortality after elective abdominal aortic aneurysm surgery between 2002 and 2013 at National Health Service hospitals in England: less benefit for women compared with men.1 passage
• Sex-specific precision medicine: targeting CRT-D and other cardiovascular interventions to those most likely to benefit.1 passage
• Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.1 passage
• Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis.1 passage
• Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry.1 passage
• Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.1 passage
• Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data.1 passage
• Should NICE guidelines be universally accepted for the evaluation of stable coronary disease? A debate.1 passage
• Should atrial fibrillation be considered a cardiovascular risk factor for a worse prognosis in COVID-19 patients?1 passage
• Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention?1 passage
• Significance of electrocardiogram recording in high intercostal spaces in patients with early repolarization syndrome.1 passage
• Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.1 passage
• Silencing of CCR2 in myocarditis.1 passage
• Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis.1 passage
• Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.1 passage
• Simple electrocardiographic measures improve sudden arrhythmic death prediction in coronary disease.1 passage
• Simultaneous dual-isotope solid-state detector SPECT for improved tracking of white blood cells in suspected endocarditis.1 passage
• Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease.1 passage
• Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism.1 passage
• Single-cell transcriptome analyses reveal novel targets modulating cardiac neovascularization by resident endothelial cells following myocardial infarction.1 passage
• Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry.1 passage
• Sleep arousal burden is associated with long-term all-cause and cardiovascular mortality in 8001 community-dwelling older men and women.1 passage
• Sleep disordered breathing and post-discharge mortality in patients with acute heart failure.1 passage
• Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants.1 passage
• Smoking cessation, but not reduction, reduces cardiovascular disease incidence.1 passage
• Sodium intake, life expectancy, and all-cause mortality.1 passage
• Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.1 passage
• Sonolysis in Prevention of Brain Infarction During Carotid Endarterectomy and Stenting (SONOBUSTER): a randomized, controlled trial.1 passage
• Spontaneous coronary artery dissection.1 passage
• Staging classification of aortic stenosis based on the extent of cardiac damage.1 passage
• Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial.1 passage
• Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document.1 passage
• Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC).1 passage
• Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).1 passage
• Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial.1 passage
• Statin associated lower cancer risk and related mortality in patients with heart failure.1 passage
• Statin therapy increases lipoprotein(a) levels.1 passage
• Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.1 passage
• Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies.1 passage
• Stem cell research for cardiac patients.1 passage
• Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014.1 passage
• Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.1 passage
• Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.1 passage
• Strategies for radiation dose reduction in nuclear cardiology and cardiac computed tomography imaging: a report from the European Association of Cardiovascular Imaging (EACVI), the Cardiovascular Committee of European Association of Nuclear Medicine (EANM), and the European Society of Cardiovascular Radiology (ESCR).1 passage
• Strategies in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants (NOACs) and co-medications with possible drug-drug interaction.1 passage
• Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial.1 passage
• Stress-associated neurobiological activity associates with the risk for and timing of subsequent Takotsubo syndrome.1 passage
• Stress-associated neurobiological activity is linked with acute plaque instability via enhanced macrophage activity: a prospective serial 18F-FDG-PET/CT imaging assessment.1 passage
• Stroke following percutaneous coronary intervention: type-specific incidence, outcomes and determinants seen by the British Cardiovascular Intervention Society 2007-12.1 passage
• Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction.1 passage
• Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort?1 passage
• Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe.1 passage
• Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons.1 passage
• Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis.1 passage
• Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update.1 passage
• Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein convertase subtilisin/kexin type 9 inhibitor use in heterozygous familial hypercholesterolaemia: insights from serial near-infrared spectroscopy imaging.1 passage
• Sudden adult death syndrome in m.3243A>G-related mitochondrial disease: an unrecognized clinical entity in young, asymptomatic adults.1 passage
• Sudden cardiac death among persons with diabetes aged 1-49 years: a 10-year nationwide study of 14 294 deaths in Denmark.1 passage
• Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives.1 passage
• Sudden cardiac death: the pro-arrhythmic interaction of an acute loading with an underlying substrate.1 passage
• Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries.1 passage
• Sudden death in patients with Ebstein anomaly.1 passage
• Sudden unexpected death in children with congenital heart defects.1 passage
• Suicide loss, changes in medical care utilization, and hospitalization for cardiovascular disease and diabetes mellitus.1 passage
• Supracardiac atherosclerosis in embolic stroke of undetermined source: the underestimated source.1 passage
• Surgical obesity treatment and the risk of heart failure.1 passage
• Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol.1 passage
• Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths.1 passage
• Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.1 passage
• Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease.1 passage
• Syncope clinical management in the emergency department: a consensus from the first international workshop on syncope risk stratification in the emergency department.1 passage
• Synergistic effect between ischaemic heart disease and common mental disorders and the risk of premature exit from the labour market: a nationwide register based study from Sweden.1 passage
• Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial.1 passage
• Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis.1 passage
• Systemic microvascular dysfunction in microvascular and vasospastic angina.1 passage
• Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis.1 passage
• Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.1 passage
• T1 mapping and survival in systemic light-chain amyloidosis.1 passage
• TAVI or No TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation.1 passage
• TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion.1 passage
• TRAK2, a novel regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis.1 passage
• TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery.1 passage
• Taking a stand against air pollution - the impact on cardiovascular disease.1 passage
• Takotsubo cardiomyopathy and neurogenic stunned myocardium: similar albeit different.1 passage
• Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.1 passage
• Targeting cardiovascular inflammation: next steps in clinical translation.1 passage
• Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy.1 passage
• Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy.1 passage
• Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes.1 passage
• Taxonomy of segmental myocardial systolic dysfunction.1 passage
• Telemedicine-guided, very low-dose international normalized ratio self-control in patients with mechanical heart valve implants.1 passage
• Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation.1 passage
• Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice.1 passage
• Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure-the COGNITION.MATTERS-HF cohort study.1 passage
• Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents.1 passage
• Temporal trends and changing profile of adults with congenital heart disease undergoing heart transplantation.1 passage
• Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study.1 passage
• Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry.1 passage
• Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006-2015.1 passage
• Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome.1 passage
• Temporal variations in the triggering of myocardial infarction by air temperature in Augsburg, Germany, 1987-2014.1 passage
• Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease.1 passage
• Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA).1 passage
• Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial.1 passage
• Testosterone: a hormone preventing cardiovascular disease or a therapy increasing cardiovascular events?1 passage
• The 'Digital Twin' to enable the vision of precision cardiology.1 passage
• The 'Ten Commandments' for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.1 passage
• The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.1 passage
• The 200th anniversary of the stethoscope: Can this low-tech device survive in the high-tech 21st century?1 passage
• The 2015 ESC Guidelines for the management of infective endocarditis.1 passage
• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.1 passage
• The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen.1 passage
• The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.1 passage
• The ACEF II Risk Score for cardiac surgery: updated but still parsimonious.1 passage
• The CAHP (Cardiac Arrest Hospital Prognosis) score: a tool for risk stratification after out-of-hospital cardiac arrest.1 passage
• The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies.1 passage
• The DEDICATE Trial: An independent all-comers trial of transcatheter aortic valve implantation vs. surgical aortic valve replacement in patients at low to intermediate operative risk is recruiting patients.1 passage
• The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl.1 passage
• The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction Outcomes.1 passage
• The European Society of Cardiology global scientific activities in Arabia 2015.1 passage
• The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN).1 passage
• The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.1 passage
• The MIDA Mortality Risk Score: development and external validation of a prognostic model for early and late death in degenerative mitral regurgitation.1 passage
• The Mediterranean diet, plasma metabolome, and cardiovascular disease risk.1 passage
• The National Cardiac Societies of the European Society of Cardiology.1 passage
• The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.1 passage
• The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives.1 passage
• The Stanford experience of heart transplantation over five decades.1 passage
• The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus.1 passage
• The Universal Definition of Heart Failure, risk prediction in cardiogenic shock, artificial intelligence in cardiac allograft rejection, and the genetics of dilated cardiomyopathy.1 passage
• The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling.1 passage
• The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial.1 passage
• The association between coronary graft patency and clinical status in patients with coronary artery disease.1 passage
• The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study.1 passage
• The association between physical activity and risk of mortality is modulated by grip strength and cardiorespiratory fitness: evidence from 498 135 UK-Biobank participants.1 passage
• The association between the public reporting of individual operator outcomes with patient profiles, procedural management, and mortality after percutaneous coronary intervention: an observational study from the Pan-London PCI (BCIS) Registry using an interrupted time series analysis.1 passage
• The association between vegetation size and surgical treatment on 6-month mortality in left-sided infective endocarditis.1 passage
• The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.1 passage
• The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions.1 passage
• The associations of major foods and fibre with risks of ischaemic and haemorrhagic stroke: a prospective study of 418 329 participants in the EPIC cohort across nine European countries.1 passage
• The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.1 passage
• The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade.1 passage
• The cardiovascular-dialysis nexus: the transition to dialysis is a treacherous time for the heart.1 passage
• The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort.1 passage
• The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium.1 passage
• The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016.1 passage
• The continuous heart failure spectrum: moving beyond an ejection fraction classification.1 passage
• The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics.1 passage
• The definition of the Brugada syndrome.1 passage
• The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring.1 passage
• The diastolic blood pressure J-curve remains an observational research phenomenon that has not yet been proven as causal and should not be used to make invasive treatment decisions.1 passage
• The dream of near-zero X-rays ablation comes true.1 passage
• The effect of 1.5 T cardiac magnetic resonance on human circulating leucocytes.1 passage
• The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial.1 passage
• The effect of aortic morphology on peri-operative mortality of ruptured abdominal aortic aneurysm.1 passage
• The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.1 passage
• The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?1 passage
• The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.1 passage
• The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial.1 passage
• The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.1 passage
• The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.1 passage
• The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.1 passage
• The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.1 passage
• The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.1 passage
• The end of an electrocardiographic dogma: a prominent R wave in V1 is caused by a lateral not posterior myocardial infarction-new evidence based on contrast-enhanced cardiac magnetic resonance-electrocardiogram correlations.1 passage
• The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis.1 passage
• The future of continuing medical education: the roles of medical professional societies and the health care industry.1 passage
• The future of transcatheter aortic valve implantation.1 passage
• The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement?1 passage
• The genetics underlying acquired long QT syndrome: impact for genetic screening.1 passage
• The growing non-pharmacological armamentarium for the treatment of cardiovascular diseases: from drug-coated balloons to drug-eluting stents, extracorporeal membrane oxygenation, and stem cells.1 passage
• The haemochromatosis gene Hfe and Kupffer cells control LDL cholesterol homeostasis and impact on atherosclerosis development.1 passage
• The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction.1 passage
• The heart of the ageing endurance athlete: the role of chronic coronary stress.1 passage
• The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.1 passage
• The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study.1 passage
• The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study.1 passage
• The hypoxic burden: a novel sleep apnoea severity metric and a predictor of cardiovascular mortality-Reply to 'The hypoxic burden: also known as the desaturation severity parameter'.1 passage
• The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis.1 passage
• The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent.1 passage
• The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy.1 passage
• The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.1 passage
• The impacts on healthcare when coronary angiography as the reference method for diagnostic accuracy of coronary artery disease is replaced by fractional flow reserve!1 passage
• The incidence and prognostic implications of worsening right ventricular function after surgical or transcatheter aortic valve replacement: insights from PARTNER IIA.1 passage
• The kidney in heart failure: an update.1 passage
• The lack of evidence-based therapeutic strategies for left ventricular unloading during venoarterial extracorporeal membrane oxygenation therapy calls for randomized trials.1 passage
• The left atrial appendage: from embryology to prevention of thromboembolism.1 passage
• The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC.1 passage
• The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis.1 passage
• The modified stepwise ablation guided by low-dose ibutilide in chronic atrial fibrillation trial (The MAGIC-AF Study).1 passage
• The natural history and surgical outcome of patients with scimitar syndrome: a multi-centre European study.1 passage
• The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.1 passage
• The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials.1 passage
• The new frontiers in prevention: from sports cardiology to spaceflight, and back to earth with cardiovascular disease and cancer.1 passage
• The new frontiers of imaging from echocardiography to positron emission tomography, and also what happened in the last year in digital health and imaging.1 passage
• The new postgraduate course in heart failure (PCHF): update on 1st PCHF and announcement of the 2nd PCHF. A project of the European Society of Cardiology Heart Failure Association, the ESC European Heart Academy, the Zurich Heart House and the University of Zurich.1 passage
• The novel coronary artery disease risk gene JCAD/KIAA1462 promotes endothelial dysfunction and atherosclerosis.1 passage
• The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction.1 passage
• The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge.1 passage
• The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability.1 passage
• The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults.1 passage
• The potential multiple effects of beta3-adrenergic receptor agonists on the heart protection for patients with heart failure with preserved ejection fraction.1 passage
• The power of myocardial blood flow reserve in personalizing management of patients with stable coronary artery disease. Is it time to move on from percentage of ischaemia?1 passage
• The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study.1 passage
• The research venture in arrhythmogenic right ventricular cardiomyopathy: a paradigm of translational medicine.1 passage
• The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study.1 passage
• The role of catheter ablation in the management of ventricular tachycardia.1 passage
• The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy.1 passage
• The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome.1 passage
• The role of metabolic syndrome in heart failure.1 passage
• The role of multi-modality imaging to investigate and manage anomalous right coronary artery originating from the pulmonary artery (ARCAPA) anomaly with associated coronary aneurysms presenting as acute left ventricular failure.1 passage
• The role of obesity in atrial fibrillation.1 passage
• The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization.1 passage
• The significance of COVID-19-associated myocardial injury: how overinterpretation of scientific findings can fuel media sensationalism and spread misinformation.1 passage
• The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction.1 passage
• The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association.1 passage
• The thrombotic risk of spaceflight: has a serious problem been overlooked for more than half of a century?1 passage
• The transcatheter valve technology pipeline for treatment of adult valvular heart disease.1 passage
• The utility of the nationwide readmissions database in understanding contemporary transcatheter aortic valve replacement outcomes.1 passage
• The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19'.1 passage
• The win ratio approach for composite endpoints: practical guidance based on previous experience.1 passage
• The year in cardiology 2014: arrhythmias and device therapy.1 passage
• The year in cardiology 2014: peripheral circulation.1 passage
• The year in cardiovascular medicine 2020: arrhythmias.1 passage
• Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial.1 passage
• Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.1 passage
• Three-dimensional echo guidance of percutaneous mitral paravalvular leak closure.1 passage
• Thrombo-embolic prevention after transcatheter aortic valve implantation.1 passage
• Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials.1 passage
• Thrombosis and platelets: an update.1 passage
• Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.1 passage
• Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?1 passage
• Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.1 passage
• Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD.1 passage
• Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium.1 passage
• Tilt testing remains a valuable asset.1 passage
• Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review.1 passage
• Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).1 passage
• Timing of intervention in asymptomatic patients with valvular heart disease.1 passage
• Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial.1 passage
• Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias.1 passage
• To stent or not to stent? Treating angina after ISCHEMIA-the impact of the ISCHEMIA trial on the indications for angiography and revascularization in patients with stable coronary artery disease.1 passage
• To stent or not to stent? Treating angina after ISCHEMIA-why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial.1 passage
• Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.1 passage
• Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience.1 passage
• Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum.1 passage
• Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.1 passage
• Trans-fatty acids and mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health Study.1 passage
• Transapical implantation of a transcatheter aortic valve prosthesis into a mitral annuloplasty ring guided by real-time three-dimensional cardiac computed tomography-fluoroscopy fusion imaging.1 passage
• Transcatheter aortic valve implantation in lower-risk patients: what is the perspective?1 passage
• Transcatheter aortic valve implantation or replacement? Valve durability in the context of patient life expectancy.1 passage
• Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials.1 passage
• Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis.1 passage
• Transcatheter aortic valve implantation with a new generation mechanically expanding valve in a patient with a protruding coronary stent into the sinus of Valsalva: the 'reversed-chimney' technique.1 passage
• Transcatheter aortic valve implantation: current status and future perspectives.1 passage
• Transcatheter aortic valve lithotripsy in severely calcified bicuspid aortic stenosis prior to transcatheter aortic valve implantation.1 passage
• Transcatheter aortic valve replacement in patients with concomitant mitral stenosis.1 passage
• Transcatheter aortic valve thrombosis: the relation between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke.1 passage
• Transcatheter edge-to-edge repair for tricuspid regurgitation in Barlow-type tricuspid valve prolapse.1 passage
• Transcatheter heart valve failure: a systematic review.1 passage
• Transcatheter heart valve interventions: where are we? Where are we going?1 passage
• Transcatheter left ventricular reshape of apical ischaemic aneurysm achieves left ventricular remodelling, improves wall motion, causes papillary muscle approximation, and a reduction of secondary MVR.1 passage
• Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes.1 passage
• Transcatheter mitral valve replacement after transcatheter direct annuloplasty with Cardioband.1 passage
• Transcatheter treatment of severe tricuspid regurgitation with the MitraClip system.1 passage
• Transcatheter tricuspid valve repair and pulmonary hypertension: navigating through troubled waters.1 passage
• Transcatheter tricuspid valve repair in patients with pulmonary hypertension.1 passage
• Transcatheter tricuspid valve-in-ring placement: complex valve obstruction by hypo-attenuating leaflet thickening, hypo-attenuation affecting motion, and native tricuspid valve remnant.1 passage
• Transcaval aortic valve implantation through a partially thrombosed infrarenal aortic aneurysm.1 passage
• Transcoronary gradients of vascular miRNAs and coronary atherosclerotic plaque characteristics.1 passage
• Transcriptional dynamics of pluripotent stem cell-derived endothelial cell differentiation revealed by single-cell RNA sequencing.1 passage
• Transforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis.1 passage
• Transgenic short-QT syndrome 1 rabbits mimic the human disease phenotype with QT/action potential duration shortening in the atria and ventricles and increased ventricular tachycardia/ventricular fibrillation inducibility.1 passage
• Transition to adulthood and transfer to adult care of adolescents with congenital heart disease: a global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (ACNAP), the ESC Working Group on Adult Congenital Heart Disease (WG ACHD), the Association for European Paediatric and Congenital Cardiology (AEPC), the Pan-African Society of Cardiology (PASCAR), the Asia-Pacific Pediatric Cardiac Society (APPCS), the Inter-American Society of Ca1 passage
• Transjugular intracardiac echocardiography-guided transcatheter aortic valve implantation.1 passage
• Treatment algorithm in patients with type 2 diabetes and atherosclerotic cardiovascular disease or high/very high cardiovascular risk.1 passage
• Treatment of cardiac transthyretin amyloidosis: an update.1 passage
• Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.1 passage
• Treatments targeting inotropy.1 passage
• Trends in aortic valve replacement for aortic stenosis: a French nationwide study.1 passage
• Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany.1 passage
• Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial.1 passage
• Tricuspid regurgitation diagnosis and treatment.1 passage
• Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis.1 passage
• Triglyceride reduction in secondary atherosclerotic cardiovascular disease prevention: core concepts in contemporary therapeutic targeting.1 passage
• Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.1 passage
• Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study.1 passage
• Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes.1 passage
• Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium.1 passage
• Trying to square the circle? Integration of computed tomography data for the evaluation of mitral regurgitation.1 passage
• Tumour necrosis factor-alpha participates on the endothelin-1/nitric oxide imbalance in small arteries from obese patients: role of perivascular adipose tissue.1 passage
• Twitter promotion predicts citation rates of cardiovascular articles: a preliminary analysis from the ESC Journals Randomized Study.1 passage
• Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry.1 passage
• Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.1 passage
• U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies.1 passage
• Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies.1 passage
• Ultra-processed food intake and all-cause and cause-specific mortality in individuals with cardiovascular disease: the Moli-sani Study.1 passage
• Ultrasound of extravascular lung water: a new standard for pulmonary congestion.1 passage
• Ultrastructural features of cardiomyocytes in dilated cardiomyopathy with initially decompensated heart failure as a predictor of prognosis.1 passage
• Uncertainties and challenges in surgical and transcatheter tricuspid valve therapy: a state-of-the-art expert review.1 passage
• Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know.1 passage
• Understanding the use of observational and randomized data in cardiovascular medicine.1 passage
• Unfolding of unexpected and extreme transcatheter aortic valve distortion.1 passage
• Unhealthy lifestyles mediate only a small proportion of the socioeconomic inequalities' impact on cardiovascular outcomes in US and UK adults: a call for action for social cardiology.1 passage
• Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions?1 passage
• Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.1 passage
• Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.1 passage
• Uninterrupted vs. interrupted non-vitamin K antagonist oral anticoagulant during atrial fibrillation catheter ablation: expert opinion or true evidence?1 passage
• Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study.1 passage
• Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction.1 passage
• Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection.1 passage
• Unusual rapid progression of non-bacterial thrombotic endocarditis in a patient with bladder cancer despite undergoing intensification treatment with rivaroxaban for acute venous thromboembolism.1 passage
• Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.1 passage
• Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.1 passage
• Use of exercise capacity to improve SCORE risk prediction model in asymptomatic adults.1 passage
• Utilization and in-hospital complications of cardiac resynchronization therapy: trends in the United States from 2003 to 2013.1 passage
• Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk.1 passage
• Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function.1 passage
• Validation of the European Society of Cardiology pre-test probability model for obstructive coronary artery disease.1 passage
• Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research.1 passage
• Variable rate of stroke after transcatheter aortic valve replacement with self-expandable valves: more doubts than certainties.1 passage
• Vascular repair and regeneration in cardiometabolic diseases.1 passage
• Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing.1 passage
• Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank.1 passage
• Ventricular arrhythmia burden during the coronavirus disease 2019 (COVID-19) pandemic.1 passage
• Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.1 passage
• Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients.1 passage
• Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes.1 passage
• Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial.1 passage
• Vulnerable plaque imaging: updates on new pathobiological mechanisms.1 passage
• Vulnerable plaques and patients: state-of-the-art.1 passage
• Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.1 passage
• Weight and weight change and risk of atrial fibrillation: the HUNT study.1 passage
• Weight gain after smoking cessation does not modify its protective effect on myocardial infarction and stroke: evidence from a cohort study of men.1 passage
• What can heart failure trialists learn from oncology trialists?1 passage
• What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?1 passage
• What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?1 passage
• When genetic burden reaches threshold.1 passage
• When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.1 passage
• Where diabetes care meets cardiovascular research: our cardiovascular perspective at a Centre devoted to diabetes research and care.1 passage
• Where's the bleed? A response to Piccini et al.'s: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.1 passage
• Which biomarker to use, when to start, and how to improve adherence for reducing atherosclerotic cardiovascular disease risk?1 passage
• Whole human heart histology to validate electroanatomical voltage mapping in patients with non-ischaemic cardiomyopathy and ventricular tachycardia.1 passage
• Why do we care about coronary microvascular dysfunction and heart failure with preserved ejection fraction: addressing knowledge gaps for evidence-based guidelines.1 passage
• Widespread pain is a risk factor for cardiovascular mortality: results from the Framingham Heart Study.1 passage
• Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.1 passage
• With our powers combined: Does the pooled analysis of existing randomized data regarding treatment of atrial fibrillation in heart failure settle the case for catheter ablation?1 passage
• Women have lower chances than men to be resuscitated and survive out-of-hospital cardiac arrest.1 passage
• Women who experience a myocardial infarction at a young age have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry.1 passage
• Women with hypertrophic cardiomyopathy have worse survival.1 passage
• Workplace bullying and workplace violence as risk factors for cardiovascular disease: a multi-cohort study.1 passage
• Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy.1 passage
• XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.1 passage
• β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.1 passage